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1. Introduction 
1.1 The human immunodeficiency virus type 1 (HIV-1) 
In 1983, the human immunodeficiency virus type 1 (HIV-1) was identified to be the 
causative agent of the acquired immunodeficiency syndrome (AIDS) by scientists of 
the Pasteur Institute in Paris, France and the National Institute of Health in Bethesda, 
USA [1, 2]. 
HIV-1 belongs to the family of retroviridae defined to have a single-stranded (ss) RNA 
genome in positive-sense orientation and characterized by the possession of the 
enzyme reverse transcriptase (RT) [3]. This particular retrovirus belongs to the genus 
lentivirus (lat. lentus for slow), which is defined to have a long period of incubation 
and an extensive duration of illness [4]. Due to differences in the HIV genome, the 
virus is classified into three major groups of HIV-1 M (main phylogenetic group), N 
(non-M / non-O) and O (outliner), in which M is the most prominent. Group M is 
further subdivided into different subtypes (A – I); these are genetically and 
geographically distinct [5-7]. Most commonly found in Western Europe and North 
America is subtype B [8, 9]. 
 
Structure and genome 
The fully developed spherically structured HIV-1 particle has a diameter of about 100-
120 nm [10] (figure 1.1 (A)). It contains two copies of the genomic, ss approximately 
9.2 kilo bases (kb) RNA molecules encoding for its nine genes [3, 11]. There are 
three structural genes, namely gag, pol and env, as well as six non-structural genes, 
explicitly tat, rev, nef, vif, vpr and vpu, which are responsible for the infection of cells 
and the production of viral particles [3] (figure 1.1 (B)). RNA molecules and, in 
addition, the virus specific enzymes RT, protease (PR) and integrase (IN) are 
enclosed by a conical nucleocapsid made up of the p24 viral protein [12]. The RT is a 
heterodimer comprised of two structurally distinct subunits (p51 and p66). Its catalytic 
activity includes a RNA-dependent DNA polymerase as well as RNase H which are 
required to transcribe the ss viral RNA genome into double-stranded (ds) DNA after 
the host cell has been entered [4]. The p66 subunit contains both DNA polymerase 
and RNase H activity, while the p51 subunit lacks the domain responsible for RNase 
H activity [13-15]. The PR is essential for the maturation of the virus particle by 
cleaving non-functional polyproteins into functional proteins [16]. It is a small aspartyl 
protease and active as a symmetric homodimer, each 99 amino acids (aa) in length. 
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Each monomer contributes one critical aspartic acid forming the active enzyme [17]. 
The IN incorporates the ds proviral DNA into the chromosomal DNA of the host cell. It 
has a restriction and ligation activity [18], by (a) 3’-processing of ds proviral DNA 
ends, followed by (b) integration of the processed ends into chromosomal DNA of the 
host [19]. The capsid in turn is surrounded by a matrix, ensuring integrity of viral 
particles and enclosed by a lipid-bilayer membrane. The surface of the viral envelope 
holds 70 spikes, which are composed of three heterodimers of the viral glycoproteins 
gp120 and gp41 [20]. 
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Figure 1.1 The human immunodeficiency virus type 1. (A) Diagram of HIV-1 particle. The HIV-1 
envelope is composed of a lipid-bilayer membrane, holding receptors, composed of 
heterodimers of the glycoproteins gp120 and gp41. The integrity of viral RNA and proteins 
(protease, reverse transcriptase and integrase) is ensured by the matrix and a conical 
nucleocapsid (adapted from [21]). (B) Organization of the HIV-1 genome. HIV-1 is composed of 
three structural genes, gag, pol and env, as well as six non-structural genes, tat, rev, nef, vif, 
vpr and vpu. Transcription, translation and the cleavage by a cellular and the viral protease 
results in functional viral proteins (adapted from [22]). 
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Replication cycle 
Once virus particles are adsorbed onto the host cell, they fuse to the membrane 
(figure 1.2 (1)). Viral gp120 is comprised of binding domains for the cellular CD4-
receptor and a second, so called co-receptor, which is a chemokine receptor [23, 24]. 
This co-receptor can either be the C-C chemokine receptor type 5 (CCR5), which is 
present on macrophages (MΦ) and T cells [25] or the C-X-C chemokine receptor 
type 4 (CXCR4), which is only expressed by T cells [26]. A conformational change is 
provoked when gp120 attaches to the cellular CD4-receptor, enabling the interaction 
with the co-receptor. At the same time the viral transmembrane protein gp41 is 
allowed to get in contact with the fusion domain of the cell membrane, leading to a 
melting of the membranes. The capsid, with its content, is released into the 
cytoplasm of the cell [27] and after it dissolves, a reverse transcription complex is 
build (figure 1.2 (2)). The ss viral RNA is transcribed by the RT into a ds 
complementary DNA (cDNA) [28] (figure 1.2 (3)). This cDNA viral genome together 
with its protein complexes are transported into the nucleus, where the viral cDNA is 
integrated into the hosts’ genome due to catalysation of the IN [19, 29] (figure 1.2 
(4)). The integrated provirus can now enter genetic latency or continue with its 
replication. Transcription occurs with the help of the cellular RNA-polymerase II. The 
generated mRNA, encoding viral proteins, is subsequently spliced and transported 
into the cytoplasm in order to be translated [30] (figure 1.2 (5)). At this stage, 
structural proteins as well as full-length viral RNAs are produced. While structural 
proteins are giving the virus its shape, full-length viral RNAs hold the HIV-1 genome 
[3] (figure 1.2 (6)). Env-proteins are synthesized and glycosylated within the 
endoplasmatic reticulum (ER) and transported to the cell surface facilitated by the 
Golgi complex. After the assembly of viral proteins, protein precursor and RNA 
molecules bud from the host cell forming immature non infectious viral particles 
(figure 1.2 (7)). Maturation occurs in the forming bud or in the immature virion after 
budding. This process is initiated by proteases, which cleave polyproteins into 
individual functional HIV-1 proteins [16, 31] (figure 1.2 (8)). Figure 1.2 shows a 
schematic overview of the HIV-1 replication cycle.  
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Figure 1.2 HIV-1 Replication cycle. Virus particles are adsorbed onto the host cell and fuse to 
the membrane (1). Viral gp120 binds cellular CD4-receptor and a co-receptor. After the fusion 
of the cell membranes, the capsid, with its content, is released into the cytoplasm of the cell 
(2). The ss viral RNA is transcribed by the RT into a ds cDNA (3) and transported into the 
nucleus, where the viral cDNA is integrated into the hosts’ genome (4). Generated mRNA, 
encoding viral proteins, is spliced and transported into the cytoplasm in order to be translated 
(5). While the structural proteins are giving the virus its shape, full-length viral RNA holds the 
HIV-1 genome (6). After the assembly of viral proteins, protein precursor and RNA molecules 
bud from the host cell forming immature, non-infectious viral particles (7). Maturation occurs 
in the forming bud or in the immature virion after budding by cleavage of polyproteins into 
individual functional HIV-1 proteins (8) (adapted from [32]). 
 
Course of infection and immune response 
An HIV-1 infected person transmits viral particles via body fluids during direct contact. 
This can either occur by blood transfer or by other body fluids (e.g. seminal fluid, 
vaginal fluid and mother’s milk) via injured mucosa [33-35]. Viral particles have not 
only been isolated from body fluids but are also present in infected CD4+ T cells, MΦ 
and dendritic cells (DCs) [36-38]. MΦ and DCs of the skin (Langerhans cells, LCs) 
are most probable the first targets addressed by virus particles. After infection with 
HIV-1, these cells migrate through lymphatic vessels to the nearest lymph node, 
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which become virus reservoirs. A huge number of cells, including monocytes, MΦ 
and naive T cells are present, creating ideal replication conditions for HIV-1 [39-41]. 
The first phase of infection, the so called primary infection (figure 1.3 (1)), proceeds 
predominantly asymptomatic. In a few cases, flu-like symptoms are described within 
the first two weeks. As a result of the rapid virus replication a high virus titer of up to 
108 particles mL-1 can be detected in peripheral blood [42]. Temporarily the number 
of CD4+ T cells is significantly low. This acute viremia is in all patients associated with 
an activation of CD8+ T cells, which are then referred to as cytotoxic T cells (CTLs). 
These are able to induce cell death of HIV-1 infected cells [43, 44]. After several 
weeks, the adaptive immune response is fully initiated and HIV-1-specific antibodies 
(seroconversion) are generated. This leads to a noticeable decrease in the amount of 
virus in the peripheral blood followed by a phase of clinical latency [45, 46]. Most 
infected individuals do not show symptoms in this stage of disease (figure 1.3 (2)). 
Within this period an active virus replication occurs with a de novo synthesis resulting 
in up to 109 infectious particles per day [47]. At this point, virus particles are trapped 
and eliminated by the fully functioning immune system. The transition towards a 
symptomatic period is initiated by the breakdown of the equilibrium between virus 
replication and immune defense. As a consequence of the progressive virus 
replication, the amount of CD4+ T cells decrease slowly and the viral load increases 
[48]. The virus replicates explosively in lymphatic tissues and infected cells are 
destroyed by CTLs in that course. An ever increasing number of CD4+ T cells is 
destroyed and cannot be replaced. Thus the immune system is less capable of 
controlling HIV-1-propagation and becomes susceptible to opportunistic infections 
leading to the progression to AIDS (figure 1.3 (3)) [49]. Figure 1.3 shows the course 
of infection and immune response over time. 
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Figure 1.3 Course of infection and immune response. The phase of the primary infection (1) is 
defined by a rapid virus replication resulting in a high virus titer and a temporarily low number 
of CD4
+
 T cells. CD8
+ 
T cells become activated, inducing the cell death of HIV-1 infected cells. 
Seroconversion and the full initiation of the adaptive immune response lead to a decrease in 
the amount of virus. Most infected individuals do not show symptoms in this stage of disease 
(2). The transition towards a symptomatic period is initiated by the breakdown of the 
equilibrium between virus replication and immune defense. As a consequence of the 
progressive virus replication, the amount of CD4
+
 T cells decreases slowly and the viral load 
increases. The immune system is less capable of controlling HIV-1-propagation leading to the 
progression to AIDS (3) (adapted from [50]). 
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1.2 Innate immune response 
Innate immune responses are immediately activated upon infection non-specifically 
by pathogen-associated molecular patterns (PAMPs). PAMPs are small molecular 
motifs conserved by pathogens (e.g. lipopolysaccharides of gram-negative bacteria 
(LPS), dsRNA of certain viruses) and recognized by toll-like receptors (TLRs) of 
specific immune cells [51, 52]. These are located on epithelial surfaces of skin and 
within the gut and reproductive tract. The entering of pathogens is facilitated by 
lesions leading to the activation of immune cells placed in underlying tissues. MΦ and 
DCs play an important role, but also contribute to immune defenses throughout the 
course of infection [38, 49]. Additionally, natural killer cells (NK cells) are specialized 
cytotoxic cells of the innate immune system, recognizing infected cells to induce their 
lysis [53, 54]. However, HIV-1 is able to circumvent presentation and recognition by 
these innate immune cells. Furthermore, monocytes, MΦ and DCs provide major 
virus reservoirs [40, 41] producing high-grade infectious virus [55]. To recruit more 
immune cells such as CD4+ T cells, monocytes, MΦ and DCs secrete several 
cytokines and chemokines. The close contact of infected reservoirs and non-infected 
CD4+ T cells facilitates the transmission of viral particles. In addition, adaptive 
immune responses are activated [36, 38]. 
 
 
Figure 1.4 Activation of innate immunity by unspecific pathogen stimulation. Unspecific 
pathogen stimuli trigger the maturation of DCs, which in turn activate NK cells, resulting in the 
secretion of cytokines and chemokines and the cytolysis of infected cells (adapted from [56]). 
 
Antigen presenting cells (APCs) 
The most important APCs with a broad range of antigen presentation are DCs. They 
derive from the bone marrow, are positioned at epithelial surfaces and circulate in 
blood and lymphoid tissues in an immature state, to interact with pathogens, 
including HIV-1 [57, 58]. DCs present both self and non-self antigens on human 
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leukocyte antigen (HLA) complexes on their cell surfaces. These are in turn 
recognized by T cells in particular by their T cell receptors (TCRs) [59].  
To present non-self antigens, DCs phagocytose pathogens, which are enzymatically 
digested into smaller pieces containing epitopes. Only immunodominant epitopes of a 
pathogen are presented [60]. After phagocytosis, DCs migrate attracted by 
chemokines through the network of lymph vessels to lymph nodes to interact with 
naïve T cells. While migrating DCs undergo maturation, they lose the ability to 
phagocytose further pathogens and increase their ability to communicate with naïve 
T cells [38]. Only a strong binding affinity of HLA:epitope complexes allows the 
recognition by T cells leading to adaptive immune responses [61]. 
 
Natural killer cells (NK cells) 
Cytotoxic NK cells are specific cells of the innate immune system expressing CD16 
and CD56 on their surface. NK cells derive from the common lymphoid progenitor cell 
and differentiate and mature in bone marrow, lymph nodes, the spleen, tonsils and 
thymus before starting to circulate in the blood [62]. NK cells have characteristic 
cytoplasmic granules. These granules can be released onto the surface of the bound 
target cell, whereupon effector proteins like perforin and proteases enter the cell to 
induce cell death [63]. Activated NK cells also secrete cytokines to regulate down-
stream immune responses in reaction to pathogens [64]. 
NK cell cytotoxic activity is regulated by a balance of activating and inhibitory 
receptors. In the case of a predominant activating signal, NK cells are activated, 
likewise if inhibitory signals overbalance, activity is inhibited [65]. In addition, 
cytokines are involved in NK cell activation [64, 66]. 
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Figure 1.5 Regulation of NK cell cytotoxic activity by a balance of activating and inhibitory 
receptors. NK cells tolerate cells, displaying self molecules (red) and only small amounts of 
stress-induced self-molecules (green) (A). They become activated and selectively kill infected 
cells with down-regulated HLA class I molecules (B) or up-regulated stress-induced self-
molecules (C) (adapted from [67]). 
 
Activating receptors directly induce cell death after binding to ligands which indicate 
infection of a cell, inhibitory receptors recognize HLA class I alleles, preventing the 
killing of healthy cells [65]. HIV-1 viral particles are able to alter the expression of 
HLA class I molecules. A down-regulation of these molecules leads to an interference 
with the activation of NK cells [68, 69]. 
 
Cytokines and chemokines 
Cytokines are small signaling proteins (~25kDa) mediating immune and inflammatory 
responses and are released by various cells (e.g. NK cells, APCs, CTLs) [70-73]. The 
binding to specific cell surface receptors provokes the activation of intracellular 
pathways, leading to an up- or down-regulation of several genes and their 
transcription factors [74]. The granulocyte macrophage colony-stimulating factor 
(GM-CSF) is a hematopoietic regulator of both granulocytes and MΦ, but it can also 
potentiate their function in inflammation [75]. Interferons (IFNs) possess antiviral 
activity and can inhibit viral replication. Type I IFN-α and -β are directly induced by 
infection, while type II IFN-γ, also known as an immune IFN, is induced by mitogenic 
or antigenic stimuli [76]. Interleukins (ILs) are a large group of immunomodulatory 
proteins activating specific signalling cascades after binding to cells, thereby 
interfering with the growth, differentiation and activation of immune cells [77]. The 
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tumor necrosis factor (TNF) is a key regulator of inflammatory responses, causing a 
variety of cellular responses, including cell death, survival, differentiation, proliferation 
and migration [78]. 
Chemokines are a subgroup of cytokines, which are relatively smaller in size (8-
10kDa) [79]. Their major role is to act as a chemoattractant to guide migration of 
cells, such as DCs to lymph nodes [80]. Eotaxin (CCL11) is an important eosinophil 
attractant [81]. IFN-γ induced protein 10 (IP-10, CCL10) specifically attracts activated 
T cells, monocytes and NK cells to sites of infection [82]. The monocyte chemotactic 
protein-1 (MCP-1, CCL2) is one of the key chemokines regulating migration and 
infiltration of monocytes and MΦ in diseased tissue [83]. Monocyte interferon gamma 
inducing factor (MIG, CXCL9) is an IFN-γ inducible chemokine, produced mainly by 
DCs, B cells and MΦ, predominantly attracting memory and effector T cells [84]. MΦ 
inflammatory protein (MIP-1α, CCL3 / MIP-1β, CCL4) enhances granulocyte-
macrophage colony formation and can cause localized inflammatory reactions, 
characterized by a rapid influx of polymorphonuclear cells [85]. The chemokine called 
regulated upon activation normal T cell expressed and presumably secreted 
(RANTES, CCL5) plays an important role in homing and migration of effector and 
memory T cells during acute infection, but can also chemoattract a variety of 
additional cells, such as monocytes, NK cells and DCs [86]. 
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1.3 Adaptive immune response 
The adaptive immunity is initiated when an infection overpowers innate immune 
responses [87]. It becomes effective after several days, requiring antigen specific T 
cells (and B cells) to encounter their specific foreign antigen, delivered and presented 
on HLA molecules by DCs, to proliferate and to differentiate into effector cells (figure 
1.6) [88, 89].  
 
 
Figure 1.6 Initiation of the adaptive immune response. The maturation of immature DCs is 
triggered by the stimulation with pathogens. Mature DCs display fragmented pieces of 
pathogens on HLA class I molecules on their cell surface to activate CD8
+
 T cells, leading to 
proliferation and CTL generation (adapted from [90]). 
 
Human leucocyte antigen (HLA) complex 
Genes encoding for the HLA complex are located on the short arm of chromosome 6. 
140 genes have been described, of which about half have a known immunological 
function [91, 92]. The HLA region is the most polymorphic of the entire human 
genome to ensure a broad range of antigen presentation [93]. 
HLA complexes act as indicators that display fragmented pieces of antigens on cell 
surfaces. Those antigens can be self or non-self. Self antigens are present on 
generally every nucleated cell and are unique to that person [59]. Non-self antigens 
can be acquired in two different ways: Fragments, which are later displayed on HLA 
class II molecules, originate from particles engulfed by e.g. MΦ and digested by 
lysozymes [94]. If a virus is infecting a cell, cleaved peptides are displayed on the 
surface of HLA class I [95]. 
HLA-A, -B and -C belong to the HLA class I [96, 97]. Regarding the nomenclature, 
HLA is registered with a letter and a number, designating a specific allele (number) to 
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a given HLA locus (letter). The first two digits correspond to a group of alleles 
encoding a specific antigen. The third and fourth digits can be used to describe a 
certain subtype [98]. 
HLA molecules are heterodimers that are anchored in the cell membrane and consist 
of a single transmembrane polypeptide α-chain and a β2-microglobulin. The α-chain 
has two polymorphic domains, α1 and α2, which are able to bind peptides (figure 1.7 
(A)) [99]. These derive from cytosolic proteins generated by proteasomes, degrading 
intracellular proteins into peptides of usually 8-10 amino acids (aa) (figure 1.7 (B.1)) 
[100]. Peptides have to be translocated from the cytosol into the ER to get in contact 
with HLA class I molecules. The transporter associated with this process (TAP) is 
able to bind peptides to translocate them ATP-dependent into the ER (figure 1.7 
(B.2)). Subsequently, several molecules e.g. tapasin, calreticulin and calnexin are 
necessary for loading the peptide onto the HLA class I molecule, which then leave 
through the secretory pathway to the cell surface (figure 1.7. (B.3/4/5)) [101]. HLA 
class I molecules on DCs generally interact with CTLs, which can initiate the cell 
death of a virus-infected cell [44]. 
Unfortunately, HIV-1 found several ways to circumvent the presentation of its 
antigens. This can either result in the down-regulation of HLA molecules at the 
surface, and / or prevents the HLA molecule to reach the cell surface. In addition, 
proteasomal cleavage can be interfered; all leading to a progression of disease [102-
105]. 
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Figure 1.7 The Human leucocyte antigen (HLA) complex (A) Structure of an HLA class I 
molecule. HLA class I molecules are anchored in the cell membrane by the transmembrane α-
chain. Its polymorphic domains α1 and α2 are able to bind peptides. In addition it consists of 
the single polypeptide β2-microglobulin (adapted from [99]). (B) Schematic overview of peptide 
processing and presentation on a HLA class I molecule. Viral peptides cleaved by the cellular 
proteasome (1) are translocated into the ER (2), loaded onto the HLA class I molecule (3) and 
transported to the cell surface (4/5) [106]. 
 
Cytotoxic T cells (CTLs) 
CD8+ T cells originating in the bone marrow migrate as precursor CD8+ T cells to the 
thymus to undergo maturation. Mature naïve CD8+ T cells enter the bloodstream to 
continually circulate through lymphoid organs and tissues [107]. 
Within lymphoid organs, mature DCs (mDCs) display antigens to naïve CD8+ T cells 
allowing naïve CD8+ T cells to screen HLA class I complexes. Displayed self-antigens 
support the selection of T cell receptors (TCRs) which are able to interact with the 
specific HLA:self-antigen complex. In this way a repertoire of mature CD8+ T cells 
that can be activated by non-self antigen bound to the same HLA molecule is 
assured [88, 89]. In addition to the initial activation by HLA:non-self-antigen (DCs) 
and TCR (CTL), a supportive T cell activation mediated by co-stimulatory molecules 
such as CD80 and CD86 expressed by APCs and CD28 on CTL starts [108, 109]. 
Most TCRs are membrane-anchored heterodimers and are composed of an α- and a 
β-chain, a few of a γ- and a δ-chain. Chains are discriminated in a variable and a 
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constant region. While the constant region is responsible for the anchoring in the cell 
membrane, the variable region binds to the HLA:antigen complex [110]. Recognition 
of an HLA:antigen complex by a specific TCR leads to the differentiation and 
proliferation of naïve CD8+ T cells to effector CTLs. CTLs leave the lymphoid organ 
and enter the bloodstream to migrate to sites of infection, attracted by chemokines 
[80]. When encountering infected cells, CTLs release the cytotoxins perforin, 
granulysin and granzymes. Perforin and granulysin form pores in the membrane of 
infected cells allowing granzymes to enter the target cell inducing cell death [111]. 
However, mutated HIV-1 antigens are altering the recognition by CTLs, resulting in 
non-recognition thus in immune escape [112, 113]. 
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1.4 Antiretroviral therapy and development of resistances 
Highly active antiretroviral therapy (HAART) 
The introduction of the highly active antiretroviral therapy (HAART) in 1996 allows a 
successful treatment of HIV-1 infected patients over a long period of time [114-116]. 
The treatment’s goal is a permanent suppression of virus replication to reduce 
plasma viral load below the currently existing limit of detection of 40 copies mL-1 
plasma [117]. 
HAART includes agents of at least two distinct classes of antiretrovirals: inhibitors of 
the RT (nucleoside/nucleotide, NRTI, and non-nucleoside, NNRTI), PR inhibitors (PI), 
a fusion inhibitor, a co-receptor antagonist and IN inhibitors, targeting all steps in the 
viral replication cycle [118, 119]. The three major groups of drugs being used in the 
clinical practice are inhibitors of the RT (NRTI and NNRTI) and the PR (PI). NRTIs 
are analogues of the nucleobases cytosine, guanidine, adenosine and thymidine, 
which in contrast do not posses the hydroxyl group at the 3’-position of the 
desoxyribose, hampering the elongation of the strand in the process of DNA-
synthesis [120]. NNRTIs bind to the hydrophobic domain of the p66-subunit of the RT 
nearby the active center, interfering with the assembly of dNTPs [121]. PIs block the 
proteolytic cleavage of protein precursors, thereby inhibiting maturation of viral 
particles [122].  
 
Development of resistance and therapy failure 
The major cause of therapy failure is the development of drug resistance associated 
mutations (RAMs) [119]. RAMs may evolve quite fast in virus replication in the 
presence of drugs as a consequence of low drug pressure and the high mutation rate 
of HIV-1 [123]. 
RAMs are well characterized and localized to specific positions within the targeted 
proteins [124-126]. Once detected, therapy can be optimized according to resistance 
profile of the dominant viral strain [126]. However, in about 10% of therapy-naïve 
patients of the RESINA cohort (primary drug RESIstance in treatment-NAïve HIV-1 
infected patients), RAMs can be detected, although those patients never received 
any therapy [127, 128]. Those RAM-containing viral stains were transmitted from one 
patient to the other and persist over time [129]. The RESINA study is a multicentre 
study conducted in North Rhine-Westphalia, Germany. With about 18 million 
inhabitants, the state accounts for approximately 21% of documented HIV-1 cases in 
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Germany. Clinical data is collected and a genotypic resistance testing is performed in 
therapy-naïve HIV-1 infected individuals prior to the start of antiretroviral treatment 
[127, 128]. 
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1.5 Aim 
RAMs localize to particular genomic sites in targeted proteins and are associated 
with specific amino acid changes [124-126]. When located within HLA class I 
restricted epitopes, they can negatively influence immunogenicity by hampering the 
binding of viral peptides to the restricting HLA class I allele, changing T cell 
recognition sites or altering peptide processing by the cellular proteasome [130-140]. 
In this study, the persistence of transmitted RAMs (tRAMs) in therapy-naïve patients 
is explained by the mechanism of immune selection: in the background of specific 
HLA class I alleles, some tRAMs might be concomitant mutations evading the 
recognition by the immune system, thereby conferring the survival advantage of the 
mutated viral strain.  
A standard antiretroviral therapy without the consideration of HLA-allele mediated 
immune selection could include antiretroviral drugs that would promote a therapy 
failure by providing a selective pressure for tRAMs conferring not only resistance to 
the drug but also immune escape. The host immune response is therefore especially 
important to consider in the treatment of therapy-naïve patients already harbouring 
tRAMs. Their treatment, therefore, should be optimized using all available information 
regarding virus and host in order to facilitate a long lasting and successful therapy. 
Processing and presentation of viral peptides is influenced by a variety of factors. 
HLA class I restricted epitopes are presented by a huge variety of HLA-molecules 
ensuring broad epitope recognition. Therefore, it is necessary to establish a model 
system that allows studying immune function in the context of the whole viral particle 
and defined HLA alleles, independent of patient samples, but still close to the in vivo 
environment.  
The assessment of significant associations between HLA class I alleles and HIV-1 
tRAMs allowed for the identification of possible immune escape mutants among 
tRAMs. These in silico obtained results were verified, establishing a suitable cell 
culture model: HLA alleles of interest were over expressed on monocyte-derived DCs 
(moDCs). A VSV-G-pseudotyped lentiviral vector system was chosen to ensure (1) 
the delivery of the gene of interest independent of receptor interaction and (2) a 
stable integration and expression of the gene of interest in these non-dividing cells. 
Pseudotyping with VSV-G allows the transduction of monocytes via endocytosis. 
Lentiviral vectors were generated, carrying two HLA open reading frames (ORF) 
(HLA-A*02:01 and HLA-B*44:03) of interest aiming to deliver those HLA ORF into 
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moDCs to generate the so called recombinant DCs. These recombinant DCs, over-
expressing the HLAs of interest, were infected with HIV-1 carrying tRAMs in PR and 
RT to determine changes in immunogenicity. Differences in cytokine and chemokine 
release in the co-cultures of either CD16+CD56+ NK cells or CD8+ T cells and 
recombinant moDCs infected with HIV-1 ADA carrying different tRAMs (V82A (PR) 
and L210F (RT)), indicate cell to cell interactions leading to immune escape. Two 
possible models of cytokine and chemokine release upon infection with either HIV-1 
ADA_V82A or ADA_L210F by moDCs in the background of HLA-A*02:01 and HLA-
B*44:03 could be feasible. One is based on an increase of cytokines and 
chemokines, while the second is based on a decrease. 
Figure 1.8 shows schematically how cytokine and chemokine release can be 
interpreted according to the assumptions made of V82A (PR) being an immune 
escape mutation in the background of HLA-A*02:01 and L210F (RT) in HLA-B*44:03. 
In HLA-A*02:01 positive donors a higher release of cytokines and chemokines is, 
according to model A1, expected after infection with HIV-1 ADA_L210F than after 
infection with ADA_V82A (ratio ADA_L210F : ADA_V82A > 1). In contrast, the 
introduction of HLA-B*44:03 would result in a decrease of release when infected with 
ADA_L210F (ratio ADA_L210F : ADA_V82A ≤ 1) (figure 1.8 (A1)). Model A2 relies 
on model A1, but is based on a decrease of cytokines and chemokines (ratio 
ADA_L210F : ADA_V82A < 1 / ratio ADA_L210F : ADA_V82A ≥ 1) (figure 1.8 (A2)). 
For HLA-B*44:03 positive donors, a higher release of cytokines and chemokines is, 
according to model B1, expected after infection with HIV-1 ADA_V82A than after 
infection with ADA_L210F (ratio ADA_V82A : ADA_L210F > 1). In contrast, the 
introduction of HLA-A*02:01 would result in a decrease of release when infected with 
ADA_V82A (ratio ADA_V82A : ADA_L210F ≤ 1) (figure 1.8 (B1)). Model B2 relies on 
model B1, but is based on a decrease of cytokines and chemokines (ratio ADA_V82A 
: ADA_L210F < 1 / ratio ADA_V82A : ADA_L210F ≥ 1) (figure 1.8 (B2)). 
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Figure 1.8 Interpretation models of cytokine and chemokine release in co-cultures containing 
moDCs deriving from (A) HLA-A*02:01 and (B) HLA-B*44:03 positive donors. The influence of 
two different mutations (V82A (PR) and L210F (RT)) are evaluated in the HLA background of 
the donor and in the LV-introduced HLA-background. Grey bars represent cytokine and 
chemokine release upon encountering HIV-1 ADA including the respective possible immune 
escape mutation, purple bars the “wild type”. Differences between cytokine and chemokine 
release upon encountering the two viral strains were calculated, dividing wild type by immune 
escape mutation. A value above 1 represents an increased release in cytokines and 
chemokines upon infection with wild type viral strain and a value below 1, an increased 
release upon infection with viral strains containing the possible escape mutation. (1) 
represents an increase of cytokine and chemokine release caused by immune escape (2) a 
decrease in cytokine and chemokine levels. 
 
 
                                                                                                                                 MATERIALS  
20 
2. Materials 
2.1 Prokaryotes  
Bacterial strains 
Escherichia coli (E.coli) strain JM109 (table 2.1) were made competent for 
transformation purposes, while purchased One Shot®Top10 Competent Cells 
(Top10) (table 2.1) were made competent by the manufacturer. Both were stored 
until further use at -80°C. 
 
Table 2.1 Overview and description of bacterial strains used for transformation purposes 
Bacterial strain Genotype Manufacturer 
One Shot®Top10 Competent 
Cells 
F- mcrA ∆(mrr-hsdRMS-mcrBC) 
φ80lacZ∆M15 ∆lacX74 recA1 araD139 
∆(araleu); 7697 galU galK rpsL (StrR) endA1 
nupG 
Invitrogen, 
Darmstadt, Germany 
E. coli JM109 
e14-(McrA-) recA1 endA1 gyrA96 thi-1; 
hsdR17(rK- mK+) supE44 relA1 ∆(lac-proAB); 
[F′ traD36 proAB lacIqZ∆M15] 
Promega, 
Mannheim, Germany 
 
2.2 Eukaryotes 
Cell lines 
Cell lines, listed in table 2.2, were used for different transfection and stimulation 
assays. They were cultured in appropriate cell culture media (table 2.11) at 37 °C 
with 5 % of CO2.  
 
Table 2.2 Overview and description of cell lines used for transfection and stimulation assays 
Cell name Description Obtained from 
293T/17 SF  
(ATCC® No.: CRL-11268) 
Homo sapiens (human), embryonic kidney cell 
line, stably transfected with large T-antigen of 
simian virus 40 (SV40) 
kindly provided by  
H. Walter 
CEMx174-M7R5-EGFP-Luc 
[141] 
eGFP, Luc and CCR5 stably transfected 
CEMx174, human CD4+ T cell / B cell hybrid  
kindly provided by 
S.Pöhlmann 
PM-1 [142] 
Human T cell line, derived from HUT-78, 
expressing CXCR4 and CCR5 receptor 
kindly provided by  
P.Lusso and R.Gallo 
 
Primary cells 
CD8+ T cells, CD14+ monocytes, CD16+CD56+ NK cells were selected from PBMCs 
of healthy donors using CD8 / CD14 MicroBeads and the CD56+CD16+ NK Cell 
Isolation Kit according to the manufacturers’ protocol. HLA-A, –B and –C alleles are 
given in table 2.3. Cells were cultured in the appropriate cell culture media (table 
2.11) at 37 °C with 5 % of CO2. 
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Table 2.3 Overview of HLA-A, -B and –C alleles of healthy donors 
Healthy donor HLA-A alleles HLA-B alleles HLA-C alleles 
1 0201, 0201 1501, 5101 0702, 1502 
2 0201, 0201 3901, 5101 1203, 1502 
3 0301, 2402 0702, 4403 0702, 1601 
4 2301, 2601 5101, 4403 0401, 1203 
 
2.3 Nucleic acids 
Oligonucleotides 
Oligonucleotide primer for polymerase chain reaction (PCR) were obtained from 
Eurofins MWG, Ebersberg, Germany and real-time PCR oligonucleotide primer and 
probes from TIB MOLBIOL, Berlin, Germany. The Oligo(dT)18 primer was purchased 
from Thermo Fisher Scientific, Schwerte, Germany. Sequences (5’3’) of 
oligonucleotide primer are listed in table 2.4.  
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Table 2.4 Overview and sequence of oligonucleotide primer and probes 
Oligonucleotide name Sequence 5’ 3’ 
(a) Used for the amplification of HLA-ORF from cDNA [143] 
HLA-A_5’-Bam TATAGGATCCGATTCTCCCCAGACGCCGAGG 
HLA-A_3’-Nsi-6His 
GGGGTCATGCATTCAATGATGATGATGATGATGCACTTTACAAGCTGT
GAGAGACAC 
HLA-B_5’-Bam TATAGGATCCCACCCGGACTCAGAATCTCCT 
HLA-B_3’-Nsi-6his 
GGGCGCATGCATTCAATGATGATGATGATGATGAGCTGTGAGAGACA
CATCAGAGCC 
HLA-C_5’-Bam TATAGGATCCTTCTCCCCAGACGCCGAGA 
HLA-C_3’-Nsi-6His 
GGGGTCATGCATTCAATGATGATGATGATGATGGGCTTTACAAGCGA
TGAGAGACTC 
    
(b) used for the amplification of HIV-1 pol, HLA-ORF in pHR’SIN-cPPT-SEW and amplification 
and sequencing of ligation products in pCR2.1
®
-TOPO
®
TA 
HIV-pol-5’ GAAGAAATGATGACAGCATGTCAGGG 
HIV-pol-3’ TAATTTATCTACTTGTTCATTTCCTCCAAT 
SEW-5'-HLA-ORF TATTTGAATTAACCAATCAG 
SEW-3'-HLA-ORF TGATACAAAGGCATTAAAGC 
TOPO-5’ GTAAAACGACGGCCAG 
TOPO-3’ CAGGAAACAGCTATGAC 
 
(c) Used for site directed mutagenesis (SDM) 
PR_V82A-5’ TATTAGTAGGACCTACACCTGCCAACATAATTGGAAGAAATCTG 
PR_V82A-3’ CAGATTTCTTCCAATTATGTTGGCAGGTGTAGGTCCTACTAATA 
RT_L210F-5’ AGGAACTGAGACAACATCTGTTCAGGTGGGGATTT 
RT_L210F-3’ AAATCCCCACCTGAACAGATGTTGTCTCAGTTCCT 
 
(d) Used for Real-time PCR [144] 
Albumin-5’ TGAAACATACGTTCCCAAAGAGTTT 
Albumin-3’ CTCTCCTTCTCAGAAAGTGTGCATAT 
Albumin-Probe 6FAM-TGCTGAAACATTCACCTTCCATGCAGA-BBQ 
β-Actin-5’ GCGAGAAGATGACCCAGATC 
β-Actin-3’ CCAGTGGTACGGCCAGAGG 
β-Actin-Probe 6FAM-CCAGCCATGTACGTTGCTATCCAGGC-BBQ 
WPRE-5’ CCGTTGTCAGGCAACGTG 
WPRE-3’ AGCTGACAGGTGGTGGCAAT 
WPRE-Probe 6FAM-TGCTGACGCAACCCCCACTGGT-BBQ 
 
Plasmids 
The cloning plasmid pCR2.1®-TOPO®TA was part of the TOPO®TA Cloning® Kit 
obtained from Invitrogen, Darmstadt, Germany. Plasmids to generate lentiviral 
vectors were kindly provided by Dr. U. Dietrich and Prof. Dr. C. Münck. The plasmid 
used for the generation of recombinant HIV-1 was kindly provided by Prof. Dr. M. 
Stevenson. All plasmids were transformed in E.coli JM109 for storage as well as for 
duplication purposes. Table 2.5 gives an overview and short description of the 
plasmids used.  
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Table 2.5 Overview, specifications and maps of plasmids 
Plasmid Specifications Obtained from 
pHR'SINcPPT-
SEW 
(9659bp) 
[145] 
Lentiviral expression vector; AmpR 
SFFV promoter in front of reporter gene 
eGFP, ψ-Signal, HIV-1-5'-LTR und 3'-SIN-
LTR 
kindly provided by Dr. U. Dietrich, 
GSH Frankfurt, Germany 
 
5'-LTR ∆3'-LTRRRE cPPT
ΨU3 R U5 R U5eGFP WPRESFFV
 
  
  
pCMV∆R8.91 
(12150bp) 
[146] 
Lentiviral expression vector, AmpR 
coding for HIV-1 proteins 
(gag, pol, rev, tat); CMV-IE promoter 
kindly provided by Dr. U. Dietrich, 
GSH Frankfurt, Germany 
 
CMV
gag pro
pol
polyA
RRE
rev
tat
 
  
  
pM.DG 
(6363bp) 
[147] 
expression vector coding for VSV-G 
(Vesicular stomatitis virus G glycoprotein), 
AmpR 
kindly provided by Prof. Dr. C. Münck, 
Heinrich-Heine University, Düsseldorf, 
Germany 
 
VSV-G polyACMV
 
  
  
pADA 
(14834bp) 
[148] 
full-length HIV-1 clone, AmpR 
Kindly provided by Prof. Dr. M. 
Stevenson, Center for AIDS research, 
MA, USA 
 
5'-LTR MA  CA  NC  p6
PR      RT      IN
5'-LTR
vpr
vif vpu
gp120    gp41
nef
pol
gag
rev
tat
 
 
 
Molecular weight size marker 
GeneRulerTM 1 kb Ladder (Fermentas, St.Leon, Germany) was used in agarose gel 
electrophoresis to estimate the size of DNA fragments.  
 
                                                                                                                                 MATERIALS  
24 
2.4 Enzymes 
Specific-buffers for each restriction enzyme used as well as bovine serum albumin 
(BSA) were provided with the restriction enzymes by the manufacturer. Table 2.6 
shows the enzymes and their manufacturer. 
 
Table 2.6 Overview of restriction enzymes and other enzymes used for work with nucleic acids  
Enzyme Manufacturer 
BamHI-HF 
DpnI 
EcoRI 
NsiI 
Sbfl-HF 
New England Biolabs, Frankfurt a.M., 
Germany 
shrimp alkaline phosphatase (SAP) Fermentas, St. Leon, Germany 
SpeI 
New England Biolabs, Frankfurt a.M., 
Germany 
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2.5 Antibodies and isotype controls 
Monoclonal antibodies were used in flow cytometry to characterize eukaryotic cells. 
Table 2.7 lists these antibodies and antibody specific information. 
 
Table 2.7 Overview of (a) antibodies and (b) isotype controls used for flow cytometry 
Antigen Clone 
Isotype 
(mouse) 
Conjugated 
dye 
Used 
Dilution 
Manufacturer 
(a) Antibodies 
HLA-ABC G46-2.6 IgG1, ĸ PE 1:50 
HLA-DR TU36 IgG2b, ĸ FITC 1:50 
BD Biosciences, 
Heidelberg, Germany 
CD3 BW264/56 IgG2a, ĸ VioBlue 1:50 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
CD4 RPA-T4 IgG1, ĸ APC 1:50 
CD8 SK1 IgG1, ĸ PerCP 1:50 
BD Biosciences, 
Heidelberg, Germany 
CD14 TÜK4 IgG2a, ĸ PE 1:50 
CD16 VEP13 IgM FITC 1:50 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
CD25 M-A251 IgG1, ĸ PE 1:50 
BD Biosciences, 
Heidelberg, Germany 
CD56 AF12-7H3 IgG1, ĸ PE 1:50 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
CD80 B7-1 IgG1, ĸ PE 1:50 
CD83 HB15e IgG1, ĸ PE 1:50 
CD86 2331 (FUN-1) IgG1, ĸ PE 1:50 
BD Biosciences, 
Heidelberg, Germany 
6xHis GG11-8F3.5.1 IgG2b, ĸ FITC 1:200 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
      
(b) Isotype controls 
G155-178 IgG2a, ĸ Biotin 
27-35 IgG2b, ĸ FITC 
APC 
MOPC-21 IgG1, ĸ 
PE 
BD Biosciences, 
Heidelberg, Germany KLH 
(keyhole 
limpet 
hemocyanin) 
IS5-20C4 IgM FITC 
1:50 
Miltenyi Biotec, 
Bergisch Gladbach, 
Germany 
Streptavidin-Phycoerythrin (SAv-PE) PE 1:100 
BD Biosciences, 
Heidelberg, Germany 
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2.6 Reagent kits 
Reagent kits were applied to perform some experiments or preparation procedures. 
These kits are listed in table 2.8. 
 
Table 2.8 Overview of reagent kits 
Reagent Kit Manufacturer 
(a) Used for the purification of nucleic acids 
NucleoBond®Xtra Maxi 
NucleoSpin®Tissue 
NucleoSpin®Gel and PCR Clean-up 
NucleoSpin®Plasmid 
NucleoSpin®RNA Blood 
Macherey-Nagel, Düren, Germany 
AllPrep DNA/RNA Mini Kit Qiagen, Hilden, Germany 
 
(b) Used for different PCR based techniques 
HotStarTaq DNA Polymerase Qiagen, Hilden, Germany 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems, Darmstadt,Germany 
Maxima® Reverse Transcripase Fermentas, St. Leon, Germany 
QuikChange®Site-Directed Mutagenesis Kit Stratagene, Waldbronn, Germany 
Light Cycler® 480 Probes Master Roche Applied Science, Mannheim, Germany 
Protector RNase Inhibitor Roche Applied Science, Mannheim, Germany 
  
(c) Used for nucleic acid sequencing 
ViroSeq® HIV-1 Genotyping System Abbott Molecular, Wiesbaden, Germany 
BigDye® Terminator v3.1 Invitrogen, Darmstadt, Germany 
  
(d) Used for cloning purposes 
TOPO®TA Cloning® Kit, including  
pCR2.1®-TOPO®TA and One Shot®Top10 
Competent Cells 
Invitrogen, Darmstadt, Germany 
Quick LigationTM Kit New England Biolabs, Frankfurt a.M., Germany 
 
(e) Used for protein detection 
Bradford Protein Assay Biorad, München, Germany 
Cytokine Human 25-Plex Panel Invitrogen, Darmstadt, Germany 
 
(f) Used for the isolation of specific cell types 
CD56+CD16+ NK Cell Isolation Kit 
CD8 MicroBeads, human 
CD14 MicroBeads, human 
Miltenyi Biotec, Bergisch Gladbach, Germany 
 
(g) Used for the transfection of cells 
FuGENE® HD Transfection Reagent Promega, Mannheim, Germany 
 
(h) Used for the detection and quantification of HIV 
Architect HIV Ag/Ab Combo 
RealTime HIV-1 Assay 
Abbott Diagnostics, Wiesbaden, Germany 
 
2.7 Chemical products and reagents 
For the preparation of certain solutions described inhere chemical products and other 
reagents were used. Table 2.9 shows the chemical product or reagent and its 
manufacturer. 
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Table 2.9 Overview of chemical products and reagents 
Chemical product / reagent Manufacturer 
6x DNA Loading Dye Fermentas, St. Leon, Germany 
Ampicillin Sigma-Aldrich, Taufkirchen, Germany 
Ampuwa, aqua ad injectabilia DelterSelect, Pfullingen, Germany 
BD Cytofix / CytopermTM –buffer 
BD Perm / WashTM –buffer 
Becton Dickinson, Heidelberg, Germany 
β-Mercaptoethanol AppliChem, Darmstadt, Germany 
Deoxyribonucleic acid, low molecular weight from 
salmon sperm 
Sigma-Aldrich, Taufkirchen, Germany 
Dimethyl sulfoxide (DMSO) AppliChem, Darmstadt, Germany 
Dulbecco’s Phoshate-buffered Saline (1x) (D-
PBS) 
Invitrogen, Darmstadt, Germany 
Empigen® BB detergent Sigma-Aldrich, Taufkirchen, Germany 
Ethanol Roth, Karlsruhe, Germany 
Ethidiumbromid Roth, Karlsruhe, Germany 
Ethylenediaminetetraacetic acid (EDTA) AppliChem, Darmstadt, Germany 
Fetal Bovine Serum (FBS) Invitrogen, Darmstadt, Germany 
Ficoll-PaqueTM PLUS GE Healthcare, Freiburg, Germany 
Gibco® Dulbecco’s Modified Eagle Medium (D-
MEM) GlutaMAXTM 
Gibco® RPMI 1640 GlutaMAXTM 
Invitrogen, Darmstadt, Germany 
Glucose AppliChem, Darmstadt, Germany 
Glycerol Calbiochem, Schwalbach, Germany 
GM-CSF, human Miltenyi Biotec, Bergisch Gladbach, Germany 
Hi-DiTM Formamide Invitrogen, Darmstadt, Germany 
Human serum Sigma-Aldrich, Taufkirchen, Germany 
Hydrogen chloride (HCl) Roth, Karlsruhe, Germany 
IL-2, human Roche Applied Science, Mannheim, Germany 
IL-4, human Miltenyi Biotec, Bergisch Gladbach, Germany 
Isopropanol Sigma-Aldrich, Taufkirchen, Germany 
LB-Agar – Powder according to Lennox 
LB-Media – Powder according to Miller 
AppliChem, Darmstadt, Germany 
LE Agarose Biozym, Hessisch Oldendorf, Germany 
Lectin (Phytohemagglutinin PHA-M) from 
Phaseolus vulgaris (red kidney bean) 
Sigma-Aldrich, Taufkirchen, Germany 
MACSQuant Bleach Solution 
MACSQuant Running –buffer 
MACSQuant Storage Solution 
MACSQuant Washing Solution 
Miltenyi Biotec, Bergisch Gladbach, Germany 
Magnesium chloride (MgCl2) Merck, Darmstadt, Germany 
Magnesium sulfate (MgSO4) Merck, Darmstadt, Germany 
H2O for analysis Merck, Darmstadt, Germany 
Paraformaldehyd (PFA) Electron, München, Germany 
Penicillin / Streptavidin Invitrogen, Darmstadt, Germany 
Polyethylene glycol (PEG) ICN Biomedicals, Inc., Aurola, OH, USA 
Puromycin dihydrochloride Sigma-Aldrich, Taufkirchen, Germany 
SephadexTM G-50 Superfine Merck, Darmstadt, Germany 
S.O.C. Medium Invitrogen, Darmstadt, Germany 
Sodium azide (NaN3) AppliChem, Darmstadt, Germany 
TAE -buffer (50x) 5 Prime, Hamburg, Germany 
Tris base Merck, Darmstadt, Germany 
0.25 % Trypsin-EDTA (1x), Phenol Red Invitrogen, Darmstadt, Germany 
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2.8 Buffers and Solutions 
Certain solutions and buffers were prepared with the ingredients and concentration 
listed in table 2.10. 
 
Table 2.10 Overview of buffer and solutions 
Buffer / Solution Components Concentration 
PEG 30 mM 
DMSO 5 % (w/v) 
MgCl2 10 mM 
Transformation and  
storage-buffer (TSB) 
MgSO4 10 mM 
Tris pH 8.0 10 mM 
Tris-EDTA (TE) buffer 
EDTA 1 mM 
FBS 4 % (v/v) 
FACS wash in D-PBS 
NaN3 0.1 % (w/v) 
D-PBS 500 mL 
EDTA 1 mM MACS buffer 
human serum 1 % (v/v) 
 
2.9 Media 
Media for bacterial culture 
Transformed bacteria were plated on LB-agar dishes supplemented with ampicillin. 
For this purpose, 40 g LB-agar powder according to Lennox were dissolved in 1000 
mL H2O. 100 µg mL
-1 ampicillin were added and approximately 20 mL LB-agar were 
poured in each dish. For the growth of transformed bacteria in LB-media 
supplemented with ampicillin, 25 g LB-medium powder according to Miller were 
dissolved in 1000 mL H2O. 100 µg mL
-1 ampicillin was added.  
 
Media for cell culture 
Used eukaryotic cell types require different culture media and suitable components 
according to their needs. In table 2.11 cell types and the composition of their culture 
media is listed.  
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Table 2.11 Overview of culture media with appropriate components for eukaryotic cell types 
Eukaryotic cell type Components Comments 
(a) Cell lines 
Gibco® D-MEM GlutaMAXTM 
10 % FBS (v/v) 
50 U mL-1 penicillin 
Adherent cells: DMEM10 
 
- 293T / 17 SF 
50 µg mL-1 streptomycin 
Storage at 4 °C,  
referred to as DMEM10 
Gibco® RPMI 1640 GlutaMAXTM 
10 % FBS (v/v) 
50 U mL-1 penicillin 
Suspension cells: RPMI10 
 
- CEMx174-M7R5-
EGFP-Luc 
- PM-1 50 µg mL
-1 streptomycin 
Storage at 4 °C,  
referred to as RPMI10 
add 1 µg mL-1 puromycin for 
selection of CEMx174-M7R5-
EGFP-Luc 
   
(b) Primary cells 
Gibco® RPMI 1640 GlutaMAXTM 
5 % human serum (v/v) 
50 U mL-1 penicillin 
50 µg mL-1 streptomycin 
Negative fraction of positive 
selected CD14+ monocytes 
20 U mL-1 IL2 
Storage at 4 °C,  
add IL-2 freshly 
Gibco® RPMI 1640 GlutaMAXTM 
1 % human serum (v/v) 
50 U mL-1 penicillin 
50 µg mL-1 streptomycin 
1000 U mL-1 GM-CSF 
CD14+ monocyte derived 
dendritic cells 
200 U mL-1 IL-4 
Storage at 4 °C  
Every second day 100-200 µL 
of R1 GM-CSF/IL-4 needs to be 
added 
 
 
Gibco® RPMI 1640 GlutaMAXTM 
5 % human serum (v/v) 
50 U mL-1 penicillin 
50 µg mL-1 streptomycin 
1000 U mL-1 GM-CSF 
200 U mL-1 IL-4 
Co-cultures of moDCs and 
CD8+ T or CD16+CD56+ NK 
cells 
20 U mL-1 IL-2 
Storage at 4 °C 
Every second day 100-200 µL 
of R1 GM-CSF/IL-4 needs to be 
added 
 
 
2.10 Devices and Consumables 
Consumables made from plastics or glass were obtained from Eppendorf, Hamburg, 
Germany; Falcon, Heidelberg, Germany; Greiner, Frickenhausen, Germany; 
Sarstedt, Nümbrecht, Germany; Millipore, Eschborn, Germany; Starlab, Ahrensburg, 
Germany; TPP, Trasadingen, Schweiz; Roche Applied Science, Mannheim, 
Germany; Thermo Fisher Scientific, Schwerte, Germany; Diversified Biotech, 
Dedham, MA, USA; ratiolab, Dreieich, Germany; Roth, Karlsruhe, Germany; VWR, 
Darmstadt, Germany; Schott, Mainz, Germany and Corning Incorporated, 
Wiesbaden, Germany. Table 2.12 lists the devices. 
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Table 2.12 Devices 
Device Specification Manufacturer 
Microcentrifuge 
5417C Eppendorf, Hamburg, Germany 
S2 
2K15 Sigma, Osterode am Harz, Germany 
S3 Z216MK Hermle, Wehingen, Germany 
 
Medium bench centrifuge 
S2 (bacteria) Megafuge® 1.OR Heraeus, Hanau, Germany 
S3 (cell culture) Z383K Hermle, Wehingen, Germany 
 
Plate centrifuge 
Typ 415 Sigma, Osterode am Harz, Germany 
S2 
Z300 Hermle, Wehingen, Germany 
   
Incubator 
S2 (bacteria) InnovaTM 4900 New Brunswick, Nürtingen, Germany 
S3 (cell culture) CO2 Incubator MCO-2OAIC Sanyo, Wiesloch, Germany 
 
Electrophoresis Devices: 
BioRad Power Pac 300 Sub-Cell® GT 
Sub-Cell® GT Cell 
Gel DocTM 
Biorad, München, Germany 
 
Fluorescence Microscope 
CKX41 
S3 
IX81 
Olympus, Düsseldorf, Germany 
 
Hood 
S2 (Real-time PCR) Hera Safe Heraeus, Hanau, Germany 
S3 (cell culture) Biowizard Xtra Kojair, Vilppula, Germany 
  
Other Devices: 
ABI 3130XL Genetic Analyzer Applied Biosystems, Weiterstadt, Germany 
Architect i2000SR Abbott Diagnostics, Wiesbaden, Germany 
ELx50 Microplate Strip Washer BioTek®, Bad Friedrichshall, Germany 
Eppendorf BioPhotometer plus Eppendorf, Hamburg, Germany 
LightCycler® 480 Roche Diagnostics, Mannheim, Germany 
Luminex® SDTM Luminex Corporation, Austin, TX, USA 
m2000TM Abbott Diagnostics, Wiesbaden, Germany 
MACSQuant® Analyzer Miltenyi, Bergisch Gladbach, Germany 
Nanodrop ND-1000 Spectrophotometer Peqlab, Erlangen, Germany 
PCR-Thermoblock TRIO Biometra, Göttingen, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
 
2.11 Software 
Software is needed to run certain devices but also to analyse data. Table 2.13 shows 
the software used including its application.  
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Table 2.13 Software 
Software Company Application 
FlowJo 7.6.5 
Tree Star, Inc., Ashland, OR, 
USA 
Analysis of flow cytometry data 
Geno2pheno geno2pheno.org 
Alignment of HIV-1 sequences 
with reference strain HXB2 
Lasergene® SeqMan ProTM DNASTAR, Madison, WS, USA Editing of sequencing data 
LightCycler® Software release 
1.5.0 SP3 
Roche Applied Science, 
Mannheim, Germany 
Analysis of real-time PCR data 
Luminex 100IS Software 
2.3.182 
Luminex Corpoation, Austin, 
TX, USA 
Analysis of luminex data 
MACSQuantify® 
Miltenyi, Bergisch Gladbach, 
Germany 
Analysis of flow cytometry data 
MATLAB R2010b 
The MathWorks Inc., Natick, 
MA, USA 
Statistical assessment of 
associations between tRAMs 
and HLA alleles 
Microsoft Office Excel and 
Word 2003 
Microsoft, Unterschleißheim, 
Germany 
Analysis and presentation of 
data 
Origin 7.5 SR4 Northhampton, MA, USA 
Analysis and presentation of 
luminex data 
QuickChange Primer Design 
Agilent Technologies, 
Waldbronn, Germany 
Design of mutagenic primer for 
QuickChange site-directed 
mutagenesis 
SPSS 16.0 IBM, Ehningen, Germany 
Statistical analysis of HIV-1 and 
HLA data 
 
2.12 Databases 
Databases contain a huge number of sequences or other data generated by the 
scientific community. Table 2.14 summarizes those databases used. 
 
Table 2.14 Databases 
Database URL / reference Application 
Arevir Database Local HIV database 
Access to patient HIV-1 and 
HLA data 
IMGT / HLA Database http://www.ebi.ac.uk/ipd/imgt/hla/ 
Use of basic local alignment 
search tool (BLAST) for the 
analysis of HLA sequences 
IAS-USA drug resistance 
mutation list 
[149] 
Identification of resistance 
associated mutations (RAMs) 
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3. Methods 
3.1 Standard laboratory methods 
Generation of competent E.coli JM109 
100 mL antibiotic-free LB-medium were inoculated with 5 mL freshly grown JM109 
culture and grown at 37 °C under permanent shaking until reaching an OD600 of 0.6-
0.9. Bacteria were centrifuged at 3000 g and 4 °C for 15 min, the bacterial pellet was 
resuspended in 5 mL ice-cold TSB. Aliquots of competent JM109 were stored at -80 
°C for further use.  
 
Transformation of JM109 and Top10 
50 µL competent bacteria (JM109 and Top10) stored at -80 °C, were thawed on ice 
and 1 µL plasmid-DNA (JM109), 5 µL ligation mix (JM109) or 2 µL TOPO® cloning 
reaction product (Top10) were added, respectively. After incubation for 30 min on ice, 
bacteria were heat shocked at 42 °C for 30 sec and again put on ice for 2 min before 
250 µL S.O.C. medium was added. In order to permit the expression of selectable 
markers, bacteria were incubated for 60 min at 37 °C under permanent shaking. 
Transformation approaches were plated on preheated LB-agar dishes and incubated 
over night at 37 °C. Single colonies were picked to be cultured in the appropriate 
volume of LB-media for the isolation of plasmid-DNA.  
 
Maintenance of cell lines and primary cells 
Adherent cells (e.g. 293T / 17 SF, (293T)) were grown in continuous culture as 
monolayers on 10 cm tissue culture plates. They were split twice weekly 1:10 – 1:20 
depending on their density. A confluent plate of cells was split as follows: media was 
removed by aspiration and the cells washed with D-PBS. Cells were overlaid with 
0.25 % Trypsin-EDTA (1x), Phenol Red and incubated at 37 °C for 2-3 min. Cells 
were harvested by adding D-PBS and, after centrifugation for 10 min at 300 g, 
resuspended in DMEM10 (table 2.11a). The appropriate volume was transferred in a 
fresh 10 cm plate and incubated for 3-4 days at 37 °C with 5 % of CO2. 
Cells grown in suspension (e.g. CEMx174-M7R5-EGFP-Luc and PM-1) were 
resuspended in RPMI10 (table 2.11a) and cultured in cell culture flask. They were 
split every other week 1:20 – 1:50 depending on their density. The appropriate 
volume of cell suspension was transferred into a fresh cell culture flask and RPMI10 
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was added. For the selection of CEMx174-M7R5-EGFP-Luc 1 µg mL-1 puromycin 
was added to the medium. Cells were incubated at 37 °C with 5 % of CO2. 
CD14+ primary cells were cultured in the appropriate cell culture medium (table 
2.11b) in cell culture flasks at a density of 1*106 cells mL-1 at 37 °C with 5 % of CO2. 
Every other day GM-CSF and IL-4 were added freshly to the culture. CD8+ and 
CD16+CD56+ primary cells were purified from the negative fraction of CD14+ cells on 
day eight, just before co-culturing with moDCs. The negative fraction was cultured at 
a density of 5*106 0.5 mL-1 in the appropriate medium containing IL-2 at 37 °C with 5 
% of CO2. 
 
Isolation of plasmid-DNA 
Isolation of plasmid-DNA (Mini-preparation using 5 mL culture, Maxi-preparation 
using 200 mL culture, extracting DNA from gel electrophoresis) was performed using 
reagent kits according to the manufacturers’ protocol. DNA concentration was 
determined, assessing the adsorption at a wavelength of 260 nm. The ratio of 
absorbance at λ=260 nm and λ=280 nm gives the degree of DNA quality. A quotient 
of OD260 / OD280 > 1.8 implies pure DNA. 
 
Isolation of genomic DNA from cultured cells 
Isolation of genomic DNA from cultured cells was performed using the 
NucleoSpin®Tissue reagent kit. When isolating genomic DNA and total RNA from the 
same sample of cultured cells the AllPrep DNA/RNA Mini Kit was used according to 
the manufacturers’ protocol. Concentration and quality were determined as described 
above. 
 
Isolation of total RNA from cultured cells / blood 
Total RNA from EDTA-blood was isolated using NucleoSpin®RNA Blood according to 
the manufacturers’ protocol. 400 µL whole blood, supplemented with 1.2-2 mg EDTA 
mL-1 blood was used to isolate total RNA. Concentration and quality were 
determined, aiming a OD260 / OD280 ratio of 2.  
As mentioned above, total RNA from cultured cells was isolated using the AllPrep 
DNA/RNA Mini Kit according to the manufacturers’ protocol.  
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Transfection of 293T cells 
For the transfection of 293T cells the FuGENE® HD Transfection Reagent was used 
according to the manufacturers’ protocol. 2.5*106 cells were plated in 100 mm dishes 
and incubated overnight. For the transfection of single plasmids (pHR'SINcPPT-
SEW, pHR'SINcPPT-SEW_HLA-A*02:01 and pHR'SINcPPT-SEW_HLA-B*44:03, 
pADA, pADA_V82A, pADA_L210F) 10 µg of DNA was used. For the co-transfection 
of pHR'SINcPPT-SEW / pHR'SINcPPT-SEW_HLA-A*02:01 / pHR'SINcPPT-
SEW_HLA-B*44:03, pCMV∆R8.91 and pM.DG 20 µg, 15 µg and 6 µg were used, 
respectively. 
 
Restriction digest 
For a preparative digest, 4 µg of DNA and for an analytical restriction digest 1 µg 
DNA were used. Reagents were added to the DNA as listed in table 3.1. Restriction 
digest was performed at 37 °C for one hour and DNA was loaded on an agarose gel 
for electrophoresis. 
 
Table 3.1 Pipetting scheme of analytical and preparative restriction digest 
Reagent Analytical restriction digest Preparative restriction digest 
DNA 1 µg  4 µg 
Enzyme 1 U 4 U 
Enzyme specific-buffer 1 µL 4 µL 
Optional BSA 1:10 1 µL 4 µL 
H2O for analysis add to a final volume of 20 µL add to a final volume of 40 µL 
 
Ligation of DNA-fragments, TOPO® Cloning Reaction  
Before the ligation of a DNA-fragment (insert) into a plasmid, the 5’ end of the 
enzymatically restricted plasmid was dephosphorylated by using 2 U shrimp alkaline 
phosphatase (SAP), 40 µL preparative digest, as well as 2 µL (v / v) SAP-buffer in a 
total volume of 50 µL (supplemented with H2O). Incubation was performed as 
described above.  
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For the ligation, the Quick LigationTM Kit was used according to the manufacturers’ 
protocol. Plasmid-DNA and insert were incubated in a ratio 1:3, which was calculated 
according to the following formula:  
 
insert [ng] = 3 x plasmid [ng] x (insert [bp] / plasmid [bp]). 
 
Ligation mixture was mixed as described in table 3.2 and the ligation reaction was 
completed over night at room temperature. 
The TOPO® Cloning Reaction was performed according to the manufacturers’ 
protocol of the TOPO®TA Cloning® Kit. 
 
Table 3.2 Pipetting schemes using the Quick Ligation
TM
 Kit and the TOPO
®
TA Cloning
®
 Kit 
Quick Ligation
TM
 Kit  TOPO
®
TA Cloning
®
 Kit 
Reagent Amount  Reagent Amount 
T4-DNA-.Ligase 5 U  Fresh PCR Product 4 µL 
10x T4-Ligase-buffer 1 µL  Salt Solution 1 µL 
Plasmid 3  pCR2.1®-TOPO®TA 1 µL 
Insert 1    
H2O for analysis 
add to a final volume of 10 
µL 
   
 
Site directed mutagenesis (SDM) 
For SDM the QuikChangeTM Site-Directed Mutagenesis Kit was used according to 
the manufacturers’ protocol. Reagents were combined and PCR conditions were 
performed as listed in table 3.3. This protocol permits site-specific mutagenesis in 
plasmids. It was used to generate point mutations leading to a switch in amino acids 
on proteins level.  
 
Table 3.3 Pipetting scheme and PCR-Thermoblock TRIO conditions for SDM  
Reagent Amount  Temperature [°C] Time [mm.ss] 
10x reaction-buffer 5 µL  95 00.30 
DNA template 5-50 ng  95 
Oligonucleotide #1 125 ng  55 
Oligonucleotide #2 125 ng  68 
00.30   I 
01.00   I 18 cycles 
02.00   I 
dNTP mix 1 µL     
H2O for analysis 
add to a final volume of 50 
µL 
    
PfuTurbo (2.5U) 1 µL     
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Polymerase chain reaction (PCR) 
The PCR serves as a rapid and selective amplification of small amounts of DNA 
fragments [150]. All PCR reactions discussed herein, were performed using the 
HotStarTaq DNA Polymerase Kit using the reaction mixture as listed in table 2.18. 
Reaction mixtures were placed into a PCR-Thermoblock TRIO for 45 cycles using the 
conditions listed in table 3.4.  
 
Table 3.4 Pipetting scheme and PCR-Thermoblock TRIO conditions for PCR 
Reagent Amount  Temperature [°C] Time [mm.ss] 
10x PCR-buffer 10 µL  95 15.00 
5x Q-Solution 20 µL  95 00.30 
dNTPs (10µM) 2 µL  65 00.45 
5’ forward primer (10 µM) 1 µL  72 03.00 
3’ reverse primer (10 µM) 1 µL  95 00.30 
Template DNA 1-2 µg  60 00.45 
HotStarTaq Polymerase (4 U / 
µL) 
0.5 µL  72 03.00 
 95 
 55 Ampuwa, aqua ad injectabilia 
add to a final  
volume of 
100 µL  72 
00.30         I 
00.45         I       45 cycles 
03.00         I 
 
Complementary DNA (cDNA) synthesis by reverse transcriptase PCR 
By means of the application of an enzyme, the reverse transcriptase, RNA can be 
transcribed in vitro in cDNA. For the reverse transcription 400 ng of total RNA 
isolated from blood was transcribed with MAXIMA® reverse transcriptase and 
Oligo(dt)18-primer in the presence of a RNAse Inhibitor. The mixture was generated 
as described in table 3.5. 
 
Table 3.5 cDNA synthesis using MAXIMA reverse transcriptase 
Reagent Amount  Temperature [°C] Time [mm.ss] 
Template RNA 400 ng  50 30.00 
Oligo(dT) (100 pM) 1 µL  85 05.00 
dNTP Mix (10 mM) 1 µL     
Nuclease-free H2O 
add to a final 
volume of 14.5 
µL 
    
5x RT-buffer 4 µL     
RNase Inhibitor  0.5 µL (20 U)     
Maxima® Reverse Transcriptase 1 µL (200 U)     
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Total RNA isolated from cell lines was transcribed using the High Capacity cDNA 
Reverse Transcription Kit, using 800 ng of total RNA, following the scheme listed in 
table 3.6. 
 
Table 3.6 cDNA synthesis using the High Capacity cDNA Reverse Transcription Kit 
Reagent Amount  Temperature [°C] 
Time 
[mm.ss] 
10x RT-buffer 2 µL  25 10.00 
25x dNTP Mix (100 mM) 0.8 µL  37 120.00 
10x RT Random Primers 2 µL  85 05.00 
MultiScibeTM Reverse Transcriptase 1 µL     
RNase Inhibitor 1 µL     
Nuclease-free H2O 3.2 µL     
Template RNA in 10 µL 800 ng     
 
Real-time PCR 
Using the real-time PCR technique, DNA of interest (template DNA) cannot only be 
amplified but also quantified. Oligonucleotide primers located at the 3'- and 5'-
terminus of the target DNA facilitate its amplification. Hybridized sequence-specific 
fluorescent labelled probes emit fluorescence when degraded by the 5’ nuclease 
activity of the polymerase in the course of elongation. Fluorescence is detected and 
measured in each PCR cycle in the LightCycler®480 and its increase is 
corresponding to the exponential increase of the PCR product. The real-time PCR 
can be divided into three phases, the early phase, the exponential growth phase and 
a plateau phase. In the early phase, the background noise exceeds the fluorescence 
emitted by the probe. At some point the amount rises significantly above the 
background, the cycle number is defined as the crossing point (cp). Comparing cp 
values of samples to those of standards with known copy numbers, PCR products 
can be quantified. Table 3.7 lists ingredients of the reaction as well as the incubation 
conditions.  
 
Table 3.7 Pipetting scheme and LightCycler
®
480 conditions for Real-Time PCR 
Reagent Amount  Temperature [°C] Time [mm.ss] 
Nuclease-free H2O 7 µL  95 10.00 
Forward primer (10 µM) 1 µL  95 
Reverse primer (10 µM) 1 µL  60 
00.15    I 40 cycle 
01.00    I         measurement 
Probe 1 µL     
Light Cycler® 480 Probes Master 10 µL     
Genomic DNA / cDNA 5 µL     
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Designing standard/reference for RT-PCR 
Here, the real-time PCR technique is used to determine the transducing units (TU) of 
lentiviral vectors and the lentiviral transgene expression in transduced target cells 
and is based on a protocol published by [144]. Lentiviral transgene expression is 
enhanced by the woodchuck hepatitis virus posttranscriptional regulatory element 
(WPRE), which is included in the 3’ untranslated region of the transfer plasmid 
pHR’SINcPPT-SEW. This allows the quantification of lentiviral vectors at the level of 
integrated proviral DNA and cellular lentiviral vector-mediated gene (mRNA) 
expression. To obtain accurate TU and to monitor lentiviral transgene expression in 
transduced cells, copy numbers were normalized to genomic DNA albumin and β-
actin mRNA copy number. 
The cp values of standards are used to calculate the concentration of target genomic 
DNA and cDNA of transduced cell samples. Standards were generated for albumin, 
β-actin and WPRE and set up with six samples prepared in serial 1:10 dilutions of 106 
copies. Dilutions were performed using plasmid maxi preparations and 
deoxyribonucleic acid, low molecular weight from salmon sperm (40 µg mL-1, diluted 
in TE buffer). pCR2.1®-TOPO®TA_albumin and pCR2.1®-TOPO®TA_β-actin were 
generated, isolating genomic DNA of 293T cells, amplifying albumin and β-actin 
using primer sets (table 2.4d), which were also used in the Real-Time PCR assay 
and integrating these PCR products in pCR2.1®-TOPO®TA. pHR'SINcPPT-SEW 
was used to generate the WPRE standard curve (figure 3.1). 
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Figure 3.1 Example real-time PCR amplification plots of standards and generated standard curves 
by plotting cp against the number of plasmid copies to determine the copy number of an unknown 
sample 
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The calculation of DNA-based titers, representing the number of infectious particles, 
and mRNA-based titers, corresponding to mRNA expression of the transgene, was 
calculated as follows and is given in TU mL-1.  
 
TU mL-1 =  WPRE concentration / 0.5 *albumin/β-actin concentration * total number  
of transduced cells * vector dilution factor(*) 
(*) only the most dilute vector samples were used to calculate titers 
 
Agarose gel electrophoresis 
Agarose gel electrophoresis is used for the separation of DNA-fragments according 
to their length based on distinct velocities of migration in an electrical field. In order to 
identify the size of the DNA fragments, a DNA ladder, containing DNA fragments of 
defined length as reference facilitates the estimation of size of the applied DNA-
fragment. Agarose gels used in this work are made of 1 % (w / v) agarose dissolved 
in Tris-acetate-EDTA-buffer (TAE). DNA was prepared in 6x loading dye to the 
digestion mixture or PCR product. Electrophoresis was performed in 1x TAE at 200 V 
for 40 min. DNA-fragments can be made visible using the intercalating chemical 
ethidium bromide (1 µg mL-1), which fluoresces when exposed with UV light (λ = 250 
- 310 nm). Pictures of agarose gels are documenting the fragmentation. 
 
Sequencing reaction 
For sequencing, the Sanger-method is used, which is based on chain breaks 
provoked by the assembly of dideoxynucleotides (ddNTPs) (instead of 
deoxynucleotides (dNTPs)) lacking the hydroxyl-group at their 3’ terminus leading to 
an interrupted chain elongation. Here, ddNTPs, coupled to a fluorescent dye, are 
used, which enables the separation of fragments of different lengths in a capillary 
electrophoresis and excited by laser, nucleotide sequence can be concluded from 
emitted fluorescence profile. 
For the sequencing of HIV pol, the HIV Genotyping Kit was used. A pre-mixture 
already contains the appropriate primer, the ddNTPs, dNTPs and the fluorescence 
dye and can be directly added to the sample. Here, 2 µL of sample are added to 3 µL 
of the respective primer mix (table 3.8). 
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Table 3.8 Pipetting scheme and PCR-Thermoblock TRIO conditions for sequencing reaction 
Reagent Amount  Temperature [°C] Time [mm.ss] 
PCR Product / Plasmid- DNA 2 µL  96 00.10 
BigDye® Terminator v3.1 2 µL  96 
5’- or 3’ oligonucleotide (0.3 µM) 1 µL  60 
00.10       I 
03.00       I 29 cycles 
 
Afterwards the sequence mix was purified to deplete factors from the sequencing 
reaction. To separate DNA fragments according to their molecular mass a sepharose 
column was used, following by applying the products on a gel matrix. While the 
fluorescent-marked DNA-fragments migrate through the column, the free ddNTPS 
were withheld. For the purification of the DNA of interest a Multi Screen Filter plate 
filled with SephadexTM G-50 superfine was used. The sepharose was soaked with 
300 µl water at 4 °C for at least 1 h and centrifuged at 910 g for 5 min. Template and 
Hi-DiTM Formamide, avoiding evaporation of the sample during the sequencing 
process, were added and centrifuged at 910 g for 5 min again. The purified product 
was thereby collected in the detection plate. After denaturating the DNA for 2 min at 
90 °C the detection plate containing the purified sequencing product was placed into 
the sequencer ABI 3130XL Genetic Analyzer. The sequences were analyzed with the 
program Lasergene® SeqMan ProTM. 
 
3.2 Protein detection 
Flow cytometry, Permeabilization and Staining of cells for flow cytometry 
Flow cytometry is used to identify the properties of cell subsets using specific 
antibodies to cellular proteins of interest. It is characterizing cells based on their 
granularity and size and, by using antibodies conjugated to a fluorescent dyes, intra- 
and extracellular proteins.  
Using the MACSQuant® the detection of eight different fluorescence dyes could be 
performed according to manufacture's instructions. 
In order to detect intracellular proteins, cells were permeabilized prior to flow 
cytometry. Cells were harvested, resuspended in D-PBS and BD Cytofix/CytopermTM 
Puffer according to manufacture's instructions for 20 min at 4 °C. Cells were washed 
prior to the staining with specific antibodies BD Perm/WashTM Puffer (1:10). Staining 
of intracellular as well as extracellular proteins was performed as follows: 100 µL of 
cells [106 mL-1] were stained with specific antibodies, using the appropriate dilution 
(table 2.6). After an incubation time of at least 30 min at 4 °C in the dark, cells were 
washed four times with FACS wash and run on the flow cytometer. 
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Bradford assay to determine protein content of lentiviral vector stocks and pADA 
based HIV-1 stocks 
500 µL of Bradford reagent were added to 10 µL of lentiviral vector stocks / pADA 
based HIV-1 stocks and incubated for 5 min. Absorbance was detected at 595 nm 
with a spectrophotometer and protein concentration was calculated with the help of a 
standard curve. The standard curve was generated adding 0 µg, 10 µg, 20 µg, 40 µg, 
80 µg and 100 µg BSA and 500 µL Bradford reagent. 
 
3.3 Selection of patient cohort 
The study on primary drug RESIstance in treatment-naïve HIV-1 infected patients 
(RESINA) is a multicentre study in North Rhine-Westphalia, Germany. Genotypic 
resistance testing was performed in therapy-naïve HIV-1 infected individuals prior to 
the start of antiretroviral treatment. Inclusion criteria for this analysis were 
documented HIV-1 infection, eligibility for application of HAART, the detection of 
transmitted resistance associated mutations (tRAMs) in either HIV-1 PR or RT and 
informed consent. Exclusion criteria were previous intake of antiretroviral drugs (as 
determined by self-report) and unwillingness to participate.  
139 HIV-1 infected therapy-naïve patients were analysed: HIV-1 subtype (subdivision 
of group M of HIV-1) and HLA-A, -B and -C genotype. 
Genomic DNA was extracted from patients’ whole blood using the QiaAmp Blood 
Mini Kit according to the manufacturers’ protocol. High-resolution HLA class I typing 
was performed by sequence-specific PCR [103, 151] at the Institute of Immunology 
and Genetics, Kaiserslautern, Germany.  
 
3.4 Assessment of statistically significant associations between transmitted 
resistance associated mutations (tRAMs) and HLA class I alleles 
The statistical analysis was performed with the help of Nico Pfeifer, Max Planck 
Institute for Informatics, Saarbrücken. Associations between tRAMs and HLA class I 
alleles were to be identified in order to identify potential immune escape variants 
within the well defined resistance associated mutations. Herefore, 139 HIV-1 infected 
HLA-typed therapy-naïve patients with detected transmitted resistance associated 
mutations (tRAMs) in either HIV-1 PR or RT were identified from the Arevir database 
(table 2.14).  
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Each individual of the cohort contributed a single HIV-1 sequence and a set of HLA 
class I genotypes to the analysis, resulting in a total of 6262 combinations of tRAM 
and HLA. Following Carlson et al. [152] a min count filter on the 2 x 2 contingency 
tables of all putative associations was applied, including only tests for which any bin 
in the contingency table had an observed and an expected value greater than three. 
After filtering in this way 236 putative associations remained. Statistical association 
between viral sequence and HLA class I genotypes were evaluated for these 236 
combinations with Fisher’s exact test using MATLAB R2010b. All p-values were two-
sided. Additionally, false discovery rates (FDRs), q-values, and odds ratios (OR) 
together with the corresponding 95% confidence interval as a measure of the effect 
size were reported. ORs > 1 were considered relevant as this denotes that the 
chance for a mutation is higher to be found in the background of a given HLA type 
than the chance for a mutation without this HLA type. ORs were calculated according 
to Bland and Altman [153]. For contingency tables of tests that contained a bin with a 
zero entry, we followed the convention to add 0.5 to every bin. FDRs and q-values for 
all 236 tests of association between a specific HLA type and a particular tRAM. This 
was performed according to Storey and Tibshirani [154], while conservatively 
choosing π0 equal to one. The q-value of an association test is the minimal FDR at 
which the test is accepted. All associations with FDR ≤ 0.10 were considered 
significant. 
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3.5 Generation of lentiviral vectors to produce recombinant monocyte derived 
dendritic cells (moDCs) 
Recombinant DCs, over-expressing HLA class I alleles of interest, were generated 
using monocyte derived DCs transduced by a lentiviral vector described by Naldini 
and colleagues [147]. 
Lentiviral vectors allow the integration of genes of interest in non-dividing cells. To 
generate lentiviral vectors in 293T cells three plasmids were co-transfected: (1) a 
transfer plasmid (pHR'SINcPPT-SEW), encoding the gene of interest, (2) a helper 
plasmid (pCMV∆R8.91) facilitating the expression of viral proteins, which are 
necessary for the packaging of the gene of interest into a viral particle, and (3) an 
envelope plasmid (pM.DG), encoding the envelope protein VSV-g allowing the virus 
to enter most cell types (figure 3.2). Here, the genes of interest were: eGFP (control), 
HLA-A*02:01 and HLA-B*44:03, which were chosen according to the statistical 
analysis and isolated from healthy HLA-typed donors. 
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Figure 3.2 Schematic overview of the process of generating recombinant moDCs. (A) 
Generation of transfer plasmids introducing HLA-A or -B specific ORF. (B) Generation of 
lentiviral vectors LV_GFP, LV_HLA-A*02:01 and LV_HLA-B*44:03. (C) Determination of the 
infectious titer of the lentiviral vectors LV_GFP, LV_HLA-A*02:01 and LV_HLA-B*44:03. (D) 
Determination of the protein content within lentiviral vector stocks: LV_GFP, LV_ HLA-A*02:01 
and LV_HLA-B*44:03 and a negative control 
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Generation of transfer plasmids introducing HLA-A or -B specific ORF 
cDNA was generated from total RNA isolated from whole blood of HLA-typed healthy 
donors. In order to generate HLA-A or -B specific PCR products, a PCR was 
performed using the appropriate primer pairs (table 2.4a). The addition of the 
sequence of a BamHI restriction site at the 5’ terminus and a NsiI restriction site on 
the 3’-end allowed cloning of the generated PCR product into the pCR2.1®-TOPO®TA 
cloning plasmid. In order to distinguish cell own HLA proteins from delivered HLA 
proteins, a sequence encoding for six Histidins (6his tag) was added using the PCR 
technique. Fresh PCR products were used for the Topo cloning reaction prior to 
clone the verified HLA fragment of interest into the transfer plasmid pHR'SINcPPT-
SEW using BamHI and NsiI restriction sites. 
Again, a sequencing reaction was performed to verify the presence of HLA ORF 
within the transfer plasmid. In order to confirm the expression of the proteins, 293T 
cells were transfected with the appropriate transfer plasmid. Flow cytometry permits 
to distinguish between cell own and delivered HLA proteins by measuring intracellular 
HLA-ABC and His antigens. Cells were permeabilized and stained for HLA-ABC and 
His for flow cytometric analysis.  
 
Generation of lentiviral vectors LV_GFP, LV_HLA-A*02:01 and LV_HLA-B*44:03 
Seven 100 mm dishes seeded with 293T cells were prepared for co-transfection 
pCMV∆R8.91, pM.DG and either pHR'SINcPPT-SEW, pHR'SINcPPT-SEW_HLA-
A*02:01 or pHR'SINcPPT-SEW_HLA-B*44:03. Five days post transfection, 
supernatants containing the lentiviral vectors (LV_GFP, LV_HLA-A*02:01 and 
LV_HLA-B*44:03) were harvested and cell debris was removed by centrifugation at 
300 g for 10 min at 4 °C and filtering using a 0.45 µm filter. 
 
Determination of the infectious titer of the lentiviral vectors LV_GFP, LV_HLA-
A*02:01 and LV_HLA-B*44:03 
The number of viral particles was determined by measuring p24-antigen using the 
Architect HIV Ag / Ab Combo. This assay can be used for the qualitative detection of 
HIV-1 and HIV-2 p24 core protein antigen and antibodies and is based on the ELISA 
technique. The chemiluminiscent signals of each sample are compared to an 
integrated reference control. Results are given as the ratio of sample (S) and the 
control (CO). Values greater or equal to 1.00 are considered positive. The lentiviral 
                                                                                                                              METHODS  
46 
expression vector pCMV∆R8.91 encodes among others for HIV-1 gag the structural 
polyprotein, which is processed into several functional proteins, including CA, the 
capsid protein p24. 
One cannot conclude the infectious titer determining p24 expression, therefore a real-
time PCR assay was established according to [144]. The integration of the gene of 
interest was verified and lentiviral expression of the gene of interest in transduced 
cells demonstrated. 2 mL of 293T cells were seeded in six-well plates at a 
concentration of 1*104 mL-1. 24 hours later cells were transduced with 1:10 serial 
dilutions of lentiviral vectors starting with 100 µL undiluted lentiviral vector. On day 
five cells were harvested and genomic DNA as well as total RNA were isolated using 
the same samples. cDNA was generated prior to real-time PCR assay. The DNA-
based titer as well as the mRNA-based titer were calculated. 
  
Determination of the protein content within lentiviral vector stocks: LV_GFP, LV_ 
HLA-A*02:01 and LV_HLA-B*44:03 
A standard curve was designed, by measuring the absorbance at 595 nm of known 
BSA concentrations. The slope was used to calculate the concentrations of the 
lentiviral stocks and a negative control, by determining their absorbance. 
 
3.6 Generation of infectious recombinant HIV-1 ADA: ADA_V82A, ADA_L210F 
Recombinant ADA (ADA_V82A, ADA_L210F) were generated according to the 
statistical analysis (section 2.2.4), on the basis of the well characterized HIV-1 
subtype B macrophage-tropic laboratory strain ADA [148]. Recombinant viral strains 
included the drug resistance associated mutations (RAMs) V82A in the PR and 
L210F in the RT. pADA pol ORF, comprising PR and RT was cloned in the pCR2.1®-
TOPO®TA cloning plasmid to enable an in vitro site-directed mutagenesis of position 
82 (PR) and 210 (RT), respectively. Mutagenised pADA pol ORF was cloned back 
into the pADA backbone for the generation of infectious viral particles via the 
transfection of 293T and subsequent infection of PM-1 cells. 
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Figure 3.3 Stepwise description of the generation of infectious recombinant HIV-1 ADA: 
ADA_V82A, L210F. (A) Cloning of pADA-pol in pCR2.1
®
-TOPO
®
TA. (B) Introduction of specific 
RAMs (V82A and L210F) via SDM and cloning mutagenised pols (deriving from pCR2.1
®
-
TOPO
®
TA-pol_V82A and pCR2.1
®
-TOPO
®
TA-pol_L210F) in pADA backbone. (C) Generation of 
infectious HIV-1 particles: ADA, ADA_V82A, ADA_L210F via the transfection of 293T and PM-1 
cells. (D) Determination of infectious titer of ADA, ADA_V82A, ADA_L210F. (E) Determination of 
the protein content of the HIV-1 ADA stocks: ADA, ADA_V82A and ADA_L210F. 
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Cloning of pADA-pol in pCR2.1®-TOPO®TA 
For the preparative digest of pADA-pol, pADA was digested using the restriction 
enzymes SpeI and EcoRI in EcoRI-buffer and BSA. In order to facilitate the ligation of 
pADA-pol in pCR2.1®-TOPO®TA, pCR2.1®-TOPO®TA was digested using the same 
conditions and was additionally treated with SAP. The complete reaction mixes were 
loaded onto an agarose gel and DNA-fragments of interest (pADA-pol and pCR2.1®-
TOPO®TA backbone) were extracted. Ligation was performed, generating pCR2.1®-
TOPO®TA-pol and transformation accomplished using E.coli JM109 chemically 
competent bacteria. 
 
Introduction of specific tRAMs (V82A and L210F) via SDM 
pCR2.1®-TOPO®TA-pol was used for each SDM using primer pairs: PR_V82A_5’/_3’ 
and RT_L210F_5’/_3’ (table 2.4c), followed by a DpnI digestion. SDM products 
(pCR2.1®-TOPO®TA-pol_V82A and pCR2.1®-TOPO®TA-pol_L210F) were 
transformed in JM109 chemically competent bacteria. Isolated plasmid-DNA was 
analyzed using the TOPO-5’/-3’ primer set (table 2.4b), verifying the integration of 
mutagenised pADA-pol. A sequencing reaction was carried out using the same 
primer set to confirm the presence of the respective introduced mutation in pADA-pol. 
 
Cloning mutagenised pols (deriving from pCR2.1®-TOPO®TA-pol_V82A and 
pCR2.1®-TOPO®TA-pol_L210F) in pADA backbone 
For the preparative digest of mutagenised pCR2.1®-TOPO®TA-pol, each pCR2.1®-
TOPO®TA-pol SDM was digested using SpeI and EcoRI restriction enzymes in 
EcoRI-buffer and BSA. In order to ligate mutagenised pol into the pADA backbone, 
pADA was digested using the same conditions including a SAP-treatment. The 
complete reaction mix was loaded onto an agarose gel and DNA-fragments 
(mutagenised pols and pADA backbone) were purified. Ligation was performed and 
E.coli JM109 chemically competent bacteria were transformed. Using PCR with 
isolated plasmid-DNA as template, the integration of mutagenised pol in the pADA 
backbone using the primer set: HIV-pol-5’/-3’ (table 2.4b) was verified. These PCR 
products were used to confirm the presence of the respective inserted mutations in a 
sequencing reaction using the ViroSeq® HIV-1 Genotyping System. 
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Generation of infectious HIV-1 particles ADA, ADA_V82A, ADA_L210F 
1.25*106 293T cells were seeded in a 25 cm cell culture flask. 24 hours later cells 
were transfected with either 10 µg pADA, pADA_V82A or pADA_L210F. Three days 
post-transfection 1 mL of supernatant was used to infect 106 PM-1 cells at a 
concentration of 105 cell mL-1 in a 25 cm cell culture flask. Infection was facilitated 
during an incubation at 37 °C for one hour and 5 % CO2. After adding 9 mL RPMI10, 
PM-1 cells were cultured for 24 h at the same conditions. Supernatant of 10 mL PM-1 
cell suspension was collected when cytopathic effect (CPE) was visible (figure 3.5, 
Results). Cell debris was removed by centrifugation at 300 g for 10 min followed by 
filtering supernatant through a 0.45 µm filter. 
 
Determination the infectious titer of ADA, ADA_V82A, ADA_L210F 
The number of viral particles in the supernatant was determined by means of two 
routine diagnostical tests. (1) Architect HIV Ag / Ab Combo to determine p24 
expression and (2) Real-Time HIV-1 Assay, targeting the integrase region of the 
polymerase gene, calculating HIV-1 RNA levels. Prior, to the determination of p24 
expression and mRNA integrase expression, infectious ADA, ADA_V82A, and 
ADA_L210F viral particles were inactivated using 0.1% (v/v) Empigen® BB detergent. 
Nevertheless, one could not conclude viral infectivity using these two tests. 
Therefore, 75 µL CEMx174-M7R5-EGFP-Luc cells were seeded in each well of a flat 
bottom 96 well plate at a concentration of 2*106 cell mL-1 in the first column. Cells 
were infected with serial dilutions (1:10) of ADA, ADA_V82A, and ADA_L210F viral 
particles, starting with 75 µL undiluted virus. Two hours post-infection, cells from one 
well were split into triplicates to start with the same infection conditions. Three days 
post-infection the infectious status of the cells with respect to eGFP expression were 
evaluated using fluorescence microscopy. Infected CEMx174-M7R5-EGFP-Luc cells 
express the reporter gene eGFP under the control of SIV-LTR, which is 
transactivated via the viral tat protein.  
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The infectious titer of cells was calculated according to the Kärber equation [155]:  
 
TCID50 / mL = D(n/p + 0.5) / D0 * D * V,  
 
where D is the dilution factor, D0 the first dilution step, n the number of positive wells 
and V the volume of the undiluted viral stock. 
 
Determination of the protein content of the HIV-1 ADA stocks: ADA, ADA_V82A and 
ADA_L210F 
A standard curve was designed, by measuring the absorbance at 595 nm of known 
BSA concentrations. The slope was used to calculate the concentrations of the HIV-1 
ADA stocks and a negative control, by determining their absorbance. 
 
3.7 Establishment of a cell culture model to determine the innate and adaptive 
immune response 
A cell culture model was established, based on the in silico obtained results, 
assessing significant associations between HLA class I alleles and HIV-1 RAMs. 
Lentiviral vectors were produced, to generate recombinant moDCs, over-expressing 
HLA alleles of interest. These recombinant moDCs were than infected with 
recombinant HIV-1 carrying RAMs in RT and PR. Co-cultures with CD16+CD56+ NK 
cells as part of the innate immune system and CD8+ T cells as part of the adaptive 
immune system were analyzed for differences in cytokine and chemokine release, 
indicating cell to cell interactions leading to immune escape.  
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Figure 3.4 Schematic overview of the establishment of a cell culture model to determine the 
innate and adaptive immune response. (A) Generation of CD14
+
 monocytes. (B) Transducing 
CD14
+
 monocytes with the lentiviral vectors LV_GFP, LV_HLA-A*02:01 and LV_HLA-B*44:03. 
(C) Infection of transduced moDCs with ADA, ADA_V82A and ADA_L210F. (D) Co-culture of 
HIV-1 infected LV-transduced moDCs with CD16
+
CD56
+
 NK cells or CD8
+
 T cells. (E) 
Determination of cytokine and chemokine release. 
 
Purification of CD14+ monocytes 
PBMCs were obtained by Ficoll-Hypaque density gradient centrifugation from a total 
of 500 mL whole blood. Herefore, 20 mL of whole blood mixed with 17 mL D-PBS 
each were loaded on top of 12 mL Ficoll-PaqueTM plus. After centrifugation at 400 g 
for 20 min at room temperature, the PBMCs containing cushion was harvested and 
PBMCs were washed twice with 30 mL D-PBS. CD14+ cells were isolated from these 
PBMCs using CD14 MicroBeads according to the manufacturers’ protocol. In 
general, CD14+ cells are magnetically labeled with CD14 MicroBeads and loaded 
onto MACS® LS columns and placed in a magnetic field. The magnetically labeled 
cells are retained within the column and the unlabeled cells run through. After 
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removing the column from the magnetic field, the retained CD14+ monocytes can be 
eluted as the positively selected cell fraction. PBMCs, the flow trough and the 
positively selected CD14+ monocytes were stained for CD3 and CD14 surface 
markers to monitor CD14+ monocyte purification via flow cytometry. CD14+ cells were 
cultured in the appropriate medium (table 2.11b) at 37 °C with 5 % of CO2. Cell 
maturation status can be followed staining CD14+ monocytes for CD25, CD80, CD83 
and CD86. Purified CD14+ monocytes were referred to as CD14+ monocytes until day 
six of culture, from day six onward they were termed moDCs. 
 
Transducing CD14+ monocytes with the lentiviral vectors LV_HLA-A*02:01 and 
LV_HLA-B*44:03 
Day two CD14+ monocytes were transduced with lentiviral vectors LV_HLA-A*02:01 
and LV_HLA-B*44:03 at a MOI of 1.5 (DNA-based titer). Herefore, 1*106 mL-1 
moDCs were pelleted in an FCS coated (3 min 4 °C) 15 mL tube and incubated with 
1.5*106 TU / 1*106 moDCs of lentiviral vector. Afterwards, cells were cultured at a 
density of 1*106 mL-1 in the appropriate medium (table 2.11b) at 37 °C with 5 % CO2. 
 
Infection of LV-transduced moDCs with ADA, ADA_V82A and ADA_L210F 
On day six, LV-transduced moDCs were pelleted in an FBS coated 15 mL tube and 
incubated at 105 TCID50 / 10
6 cells for one hour at 37 °C with 5 % CO2
 with HIV-1 
ADA_V82A and ADA_L210F. Afterwards, cells were cultured at a density of 1*106 
mL-1 in the appropriate medium (table 2.11b) at 37 °C with 5 % CO2.  
 
Purification of CD16+CD56+ NK cells and CD8+ T to co-culture with HIV-1 ADA 
infected LV-transduced moDCs 
The negative fraction of CD14+ monocytes was used for the purification of CD8+ T 
and CD16+CD56+ NK cells. The CD14+ monocyte negative fraction was cultured in 
the appropriate medium (table 2.11b) at 37 °C with 5 % CO2 until day eight, the day 
of the co-culture. CD16+CD56+ NK cells were purified using the CD56+CD16+ NK Cell 
Isolation Kit. Cells were stained for CD16 and CD56 to monitor CD16+CD56+ NK cell 
purification via flow cytometry. CD8+ T cells were isolated from the negative fraction 
of CD14+ monocytes and CD16+CD56+ NK cells using CD8 MicroBeads according to 
the manufacturers’ protocol. CD8+ T cells were stained for CD3 and CD8 to monitor 
CD8+ T cell purification via flow cytometry.  
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Co-culture of moDCs with either CD16+CD56+ NK or CD8+ T cells 
Purified CD16+CD56+ NK and CD8+ T cells were added in a 1:1 ratio to the LV-
transduced HIV-1 ADA infected moDCs. Afterwards, cells were cultured at a density 
of 1*106 mL-1 in the appropriate medium (table 2.11b) at 37 °C with 5 % CO2. 
 
Determination of the cytokine and chemokine release in HIV-1 infected patients 
A patient cohort was chosen, including 40 HIV-1 infected patients with pVL < 50 
(therapy-experienced) and ten with pVL > 0.5*106 (therapy-naïve), randomly 
selected. 50 µL of plasma was used to detect cytokine and chemokine secretion, 
using the human 25-plex panel, detecting several cytokines (GM-CSF, IFN-α / -γ, IL-
1β / 1RA / 2 / 2R / 4 / 5 / 6 / 7 / 8 / 10 / 12 / 13 / 15 / 17, TNF-α) and chemokines 
(eotaxin, IP-10, MCP-1, MIG, MIP-1α / 1β, RANTES) and the LUMINEX®SDTM 
according to the manufacturers’ protocol. Data was evaluated using Luminex 100IS 
Software 2.3.182.  
As a control, the plasma of nine healthy lab volunteers was analyzed. Statistical 
analysis was performed using Origin 7.5 SR4, assessing significant differences in the 
secretion of healthy volunteers and HIV-1 infected patients (p < 0.05 in student t 
test). Error bars were calculated as the standard error of the mean. 
 
Influence of the infection of moDCs with HIV-1 ADA_V82A and ADA_L210F on the 
cytokine and chemokine release of moDCs 
The influence of HIV-1 ADA infection on the cytokine and chemokine release of 
moDCs, was determined using the human 25-plex panel and the LUMINEX®SDTM 
according to the manufacturers’ protocol. Data was evaluated using Luminex 100IS 
Software 2.3.182. Here for, cell culture supernatants were harvested of single cell 
CD14+ monocytes cultures on day two, as well as supernatants of uninfected, HIV-1 
ADA_V82A and ADA_L210F infected moDCs on day eight. Supernatants were 
diluted 1:10 before the application in the luminex assay.  
Values below the limit of detection were set to the lower limit of detection and values 
equal to and above the limit of detection were set to upper limit of detection. Error 
bars were calculated as the standard error of the mean. 
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Influence of the transduction of CD14+ monocytes on the cytokine and chemokine 
release of moDCs 
The influence of LV-transduction on the cytokine and chemokine release of moDCs 
was determined using the human 25-plex panel and the LUMINEX®SDTM according 
to the manufacturers’ protocol. Data was evaluated using Luminex 100IS Software 
2.3.182. Here for, cell culture supernatants were harvested of single cell CD14+ 
monocytes cultures on day two, as well as supernatants of untransduced and LV-
transduced moDCs on day eight. The influence of the two different lentiviral vectors 
on cytokine and chemokine secretion was not observed separately. Supernatants 
were diluted 1:10 before the application in the luminex assay.  
Values below the limit of detection were set to the lower limit of detection and values 
equal to and above the limit of detection were set to upper limit of detection. Error 
bars were calculated as the standard error of the mean. 
 
Determination of cytokine and chemokine release in the co-culture of HIV-1 ADA 
infected moDCs with either CD16+CD56+ NK cells or CD8+ T cells indicating an 
immune escape of V82A (PR) or L210F (RT) in the respective HLA backgrounds 
Cell culture supernatants were harvested of day eight untransduced, uninfected 
moDCs; untransduced, HIV-1 ADA infected moDCs; LV-transduced, uninfected 
moDCs and LV-transduced, HIV-1 ADA infected moDCs. Again, cell culture 
supernatants were harvested on day ten, of the above described cell fractions, co-
cultured with either CD16+CD56+ NK cells or CD8+ T cells.  
The release of cytokines and chemokines was determined in 1:10 diluted 
supernatants using the cytokine human 25-plex panel and the LUMINEX®SDTM 
according to the manufacturers’ protocol. Data was evaluated using Luminex 100IS 
Software 2.3.182. 
Values below the limit of detection were set to the lower limit of detection and values 
equal to and above the limit of detection were set to upper limit of detection. Error 
bars were calculated as the standard error of the mean. Fold differences were 
calculated, normalizing to untransduced, uninfected moDCs and LV-transduced, 
uninfected moDCs. The ratios of fold differences were determined, for HLA-A*02:01 
positive donor: ADA_L210F : ADA_V82A and for HLA-B*44:03 positive donor: 
ADA_V82A : ADA_L210F. 
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CD14+ monocytes
+ CD16+CD56+  / CD8+ cells 
ratio moDCs 1:1
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105 TCID
50
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(un)infected moDCs
 
Figure 3.5 Schematic overview of the determination of cytokine and chemokine release in the 
co-culture of HIV-1 ADA infected moDCs with either CD16
+
CD56
+
 NK cells or CD8
+
 T cells 
indicating an immune escape of V82A (PR) or L210F (RT) in the respective HLA backgrounds 
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4. Results 
This study aimed to identify an influence of tRAMs within HIV-1 PR and RT on host 
specific innate and adaptive immune responses. A statistical analysis associating 
tRAMs within viral strains of a patient cohort of therapy-naïve HIV-1 infected 
individuals with the patients’ HLA-A, -B and –C alleles was performed to identify 
potential immune escape mutations among tRAMs. V82A (PR), a tRAM, which is 
associated with resistance to several PR inhibitors was shown to be significantly 
associated with HLA-A*02:01 and was therefore chosen for further analysis. As a 
control, L210F (RT), a mutation which has already been described to have an impact 
on the patients’ immune response in the background of HLA-B*44:03 was analyzed 
(data not shown [156]). 
A cell culture model was established, in which recombinant moDCs, over-expressing 
HLA alleles of interest were infected with recombinant ADA based HIV-1 
incorporating the respective tRAMs and responses of CD16+CD56+ NK cells and 
CD8+ T cells determined. Recombinant moDCs were generated using a lentiviral 
vector system, delivering HLA alleles of interest, here HLA-A*02:01 and HLA-B*44:03 
(figure 3.2). Transduced moDCs were subsequently infected with recombinant ADA 
based HIV-1 either comprising mutation V82A (PR) or L210F (RT) (figure 3.4). Innate 
immune responses were determined, co-culturing the transduced and infected 
moDCs with CD16+CD56+ NK cells and detecting cytokine and chemokine levels, 
while the adaptive immune response was detected in moDC / CD8+ T cell co-cultures 
(figure 3.5). 
 
4.1 Selection of patient cohort 
In order to identify potential immune escape mutations among tRAMs in HLA-
restricted epitopes, an appropriate patient cohort needed to be selected. 139 
therapy-naïve HIV-1 infected patients from the RESINA study with tRAMs in either 
PR and / or RT were enrolled. 87.7 % of these patients were of Caucasian origin and 
79.0 % were infected with HIV-1 subtype B (subtype A: 11.6 %, D: 1.4 %, G: 1.4 %, 
C: 1.4 %, F: 0.7 %, URF: 4.5 %). According to the IAS-list [125], 40 different PI 
tRAMs were detected, 10 different NRTI tRAMs and 14 different tRAMs conferring 
resistances to NNRTIs (table 4.1). 
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Table 4.1 Frequencies of PI, NRTI and NNRI tRAMs of 139 therapy-naïve patients 
HXB2 reference 
strain 
Mutation in 
the PR 
associated 
with PI 
Resistance 
Number of 
patients 
 HXB2 reference 
strain 
Mutation in 
the RT 
associated 
with NRTI 
Resistance 
Number of 
patients 
F 1  M41 L 9 
I 25  D67 N 6 
L10 
V 4  K70 R 1 
G16 E 11  L74 V 1 
I 7  L75 I 2 
M 3  M184 V 3 
R 13  L210 W 1 
K20 
T 2  T215 Y 1 
L24 I 1  E 3 
V32 I 1  
K219 
Q 6 
F 4     
I 2     
L33 
V 3  
I 54  
L 3  
HXB2 reference 
strain 
Mutation in 
the RT 
associated 
with NNRTI 
Resistance 
Number of 
patients M36 
V 2  V90 I 3 
I 8  K101 E 3 M46 
L 6  K103 N 14 
F53 L 3  A 2 
Q58 E 1  
V106 
I 10 
D60 E 9  V108 I 4 
I62 V 46  A 8 
L63 P 69  G 1 
L 2  
E138 
K 2 I64 
V 25  D 6 
K 22  
V179 
T 2 H69 
R 1  V181 C 7 
T 11  Y190 A 5 A71 
V 12  P225 H 2 
A77 I 35     
A 8     
I 9     
L 1     
V82 
T 1     
I84 V 3     
I85 V 1     
M 21     L89 
V 1     
L90 M 7     
I93 L 47     
 
HLA-typing of these patients revealed, that the HLA-A, -B and -C genotype of all 
patients showed the highest frequencies for: HLA-A*02:01, HLA-A*03:01, HLA-
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A*01:01, and HLA-A*24:02; HLA-B*07:02, HLA-B*08:01, HLA-B*44:02, and HLA-
B*51:01; HLA-C*07:02, HLA-C*07:01, HLA-C*04:01, HLA-C*06:02 (table 4.2). 
 
Table 4.2 Frequencies of HLA-A, -B and –C alleles of 139 therapy-naïve patients 
HLA-A* Allele frequency  HLA-B Allele frequency  HLA-C Allele frequency 
02:01 19.34  07:02 11.55  07:02 12.72 
03:01 13.99  08:01 9.16  07:01 11.84 
01:01 12.76  44:02 7.57  04:01 11.40 
24:02 10.29  51:01 7.17  06:02 9.21 
11:01 6.58  15:01 6.77  12:03 7.02 
68:01 5.35  35:01 6.37  05:01 6.58 
26:01 4.94  18:01 5.98  03:04 6.14 
30:01 3.29  13:02 3.19  01:02 5.70 
32:01 3.29  27:05 3.19  02:02 5.26 
23:01 2.06  38:01 3.19  03:03 4.82 
29:02 2.06  40:01 2.79  15:02 3.95 
31:01 2.06  15:03 2.39  16:01 3.07 
03:02 1.65  35:02 1.99  07:04 2.19 
25:01 1.65  35:03 1.99  02:10 1.75 
02:02 1.23  44:03 1.99  08:02 1.75 
68:02 1.23  14:02 1.59  14:02 1.32 
02:03 0.82  42:01 1.59  17:01 1.32 
02:05 0.82  57:01 1.59  08:01 0.88 
29:01 0.82  40:02 1.20  04:03 0.44 
33:01 0.82  44:05 1.20  04:29 0.44 
66:01 0.82  50:01 1.20  05:09 0.44 
01:03 0.41  52:01 1.20  12:02 0.44 
02:06 0.41  55:01 1.20  15:05 0.44 
02:17 0.41  56:01 1.20  16:04 0.44 
24:03 0.41  58:01 1.20  17:03 0.44 
24:07 0.41  13:01 0.80    
30:02 0.41  14:01 0.80    
33:03 0.41  15:02 0.80    
69:01 0.41  15:17 0.80    
74:01 0.41  35:08 0.80    
74:05 0.41  39:01 0.80    
   45:01 0.80    
   46:01 0.80    
   53:01 0.80    
   07:05 0.40    
   15:16 0.40    
   15:32 0.40    
   27:02 0.40    
   27:14 0.40    
   37:01 0.40    
   39:10 0.40    
   41:01 0.40    
   49:01 0.40    
   54:01 0.40    
   58:02 0.40    
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4.2 Assessment of statistically significant associations between tRAMs and 
HLA class I alleles 
In order to identify potential immune escape mutants among tRAMs, significant 
associations between tRAMs and HLA-A, -B and –C alleles were assessed. 
Of all 236 combinations of tRAMs in PR and RT and HLA-A, -B, and –C alleles, a 
total of 29 relevant associations were identified by Fishers exact test (explorative p-
value ≤ 0.05; OR > 1). 24 relevant associations were found between tRAMs in PR 
and different HLA alleles plus five tRAMs in RT and HLA alleles (data not shown). 
After correcting for multiple testing according to Storey and Tibshirani [154] allowing 
FDR ≤ 0.10, nine associations remained significant (table 4.3). Another approach for 
correcting for multiple tests is the Bonferroni correction. This correction is in general 
more conservative, because it requires a p-value of 0.05 / n or smaller, where n is the 
number of tests performed. Nevertheless, the two strongest associations were still 
significant after Bonferroni correction (p-value < 0.0002). These two associations 
were the combinations of V82A (PR) and HLA-A*02:01 as well as I93L (PR) and 
HLA-B*15:01.  
 
Table 4.3 Statistical significant associations between tRAMs and HLA-A, -B and –C alleles after 
correcting for multiple testing according to Storey and Tibshirani [154] 
95% confidence 
interval tRAMs  
in PR 
Associated  
HLA allele 
p-value FDR q-value 
odds 
ratio lower 
limit 
upper 
limit 
B*15:03 0.002876 0.084848 0.084848 2.29*107 1.26*106 4.16*108 
M36I 
C*12:03 0.002275 0.076699 0.076699 5.92*107 1.78*106 1.97*107 
A*03:01 0.003403 0.089246 0.089246 1.79*107 2.01*106 1.60*108 
M46L 
C*02:10 0.000659 0.038895 0.038895 5.27*107 2.72*106 1.02*109 
A*02:01 0.000112 0.026362 0.018934 3.98*107 2.24*106 7.07*108 
V82A 
C*02:10 0.000534 0.041982 0.038895 5.65*107 2.90*106 1.10*109 
I93L B*15:01 0.000160 0.018934 0.018934 8.41*106 2.56*106 2.76*107 
        
95% confidence 
interval tRAMs  
in RT 
Associated  
HLA allele 
p-value FDR q-value 
odds 
ratio lower 
limit 
upper 
limit 
A*02:01 0.001196 0.056440 0.056440 2.90*107 1.59*106 5.26*108 
V179D 
C*07:01 0.001893 0.074476 0.074476 2.16*107 2.40*106 1.94*108 
 
V82A (PR) was highly associated with HLA-A*02:01 and therefore selected for further 
analysis. L210F (RT) is a well characterized immune escape mutation in the 
background of HLA-B*44:03 and was found at a frequency of 5.0 % (7 / 139) in the 
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therapy-naïve patients. No statistically significant associations could be found (p = 
0.231) however the two-digit HLA-B*44 was significantly associated with L210F (RT) 
(p = 0.027). Thus, L210F (RT) was the second mutation used to establish the cell 
culture model. 
 
4.3 Generation of lentiviral vectors to produce recombinant monocyte-derived 
dendritic cells (moDCs) 
This part focuses on the generation of lentiviral vectors to produce recombinant 
moDCs, over-expressing either HLA-A*02:01 or HLA-B*44:03. Herefore, a lentiviral 
vector system was chosen to facilitate a stable integration of the gene of interest and 
the expression in non-dividing moDCs. 
 
Generation of transfer plasmids introducing HLA-A or -B specific ORF 
cDNA was generated from total RNA of HLA-A*02:01 and HLA-B*44:03 positive 
donors. A PCR, using appropriate primer pairs (table 2.4a) was performed to amplify 
a product containing the HLA-A*02:01 ORF with a size of 1098 bp and HLA-B*44:03 
ORF with a size of 1089 bp, introducing in addition a His-tag at the 3’end (figure 4.1). 
 
(A) 
HLA-A ORF: 1098bp
HLA-B ORF: 1089bp
HLA ORF 6xHistotal RNA cDNA
 
(B) 
 
Figure 4.1 Amplification of HLA ORF. (A) cDNA generated from total RNA of whole blood of an 
HLA-A*02:01 and an HLA-B*44:03 positive donor. HLA-A and –B specific PCR products were 
generated using HLA-A and –B specific primer sets, introducing a His-tag at the 3’ end of the 
HLA-ORF. (B) HLA-A*02:01 and HLA-B*44:03 ORF PCR products were visualized using gel 
electrophoresis. 
 
After cloning HLA-A*02:01 and HLA-B*44:03 ORF in pCR2.1®-TOPO®TA cloning 
plasmid (data not shown), HLA ORFs were ligated in the pHR'SINcPPT-SEW 
transfer plasmid, forming the product pHR’SINcPPT-SEW_HLA. A PCR was 
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performed using SEW-5’-HLA-ORF and SEW-3’-HLA-ORF (table 2.4b) to verify the 
successful integration of the inserted HLA-ORF (figure 4.2, data not shown).  
 
5'-LTR ∆3'-LTRRRE cPPT
ΨU5 SFFVR R U5HLA ORF WPRE6xHis
pHR'SINcPPT-SEW_HLA-ORF
primer binding site:
SEW-5'-HLA-ORF
primer binding site:
SEW-3'-HLA-ORF
U3
HLA-A ORF: 1098bp
HLA-B ORF: 1089bp
 
Figure 4.2 Verification of the integration of HLA-ORF in pHR’SINcPPT-SEW, analyzing 
pHR’SINcPPT-SEW_HLA-ORF clones using pHR’SINcPPT-SEW specific primer (data not 
shown). 
 
To further confirm the presence of HLA-A*02:01 and HLA-B*44:03 ORFs in the 
transfer plasmid pHR’SINcPPT-SEW, a sequencing reaction was performed using 
the same primer set (SEW-5’-HLA-ORF and SEW-3’-HLA-ORF) and as a template 
the PCR product. Sequences were aligned to published HLA sequences [93], 
showing a sequence identity ranging from of 99 % for HLA-A*02:01 to 100 % for 
HLA-B*44:03 (figure 9.1). 
In order to verify the ability of an expression of the HLA proteins HLA-A*02:01 and 
HLA-B*44:03, 293T cells were transfected with the transfer plasmids: pHR’SINcPPT-
SEW_HLA-A*02:01 and pHR’SINcPPT-SEW_HLA-B*44:03. Using flow cytometry 
cells were permeabilized and stained for His and HLA-ABC to evaluate the 
expression of the His-tagged HLA proteins. The percentages of cells expressing 
both, HLA and His-tagged (HLA-) proteins were quantified by the mean fluorescence 
intensity (MFI) of both fluorescence dyes labelling the respective antibody. The dot 
plots show an increase in double positive cells, showing those His-tagged HLA 
alleles transfected by the transfer plasmid (figure 4.3). 
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(A) (B) (C) 
   
Figure 4.3 Flow cytometry analysis to identify 293T transfected His-tagged HLA proteins. 293T 
cells were permeabilized and stained for His-FITC and HLA-ABC-PE to identify the His-tagged 
HLA proteins (A) untransfected, stained with isotype control, (B) transfected with 
pHR’SINcPPT-SEW_HLA-A*02:01 and (C) with pHR’SINcPPT-SEW_HLA-B*44:03. 
 
Table 4.4 summarizes the flow cytometry data of MFI (FITC and PE) of un-
transfected and transfected 293T cells, indicating the expression of both His-tagged 
HLA proteins, HLA-A*02:01 and HLA-B*44:03. 
 
Table 4.4 Summary of flow cytometry results of 293T cells transfected with pHR’SINcPPT-
SEW_HLA-A*02:01 and pHR’SINcPPT-SEW_HLA-B*44:03 
His–FITC and HLA-ABC–PE 
Transfectant 
% - T MFI (FITC) MFI (PE) 
Un-transfected 9.4 885 240 
pHR’SINcPPT-SEW_HLA-A*02:01 57.3 612 369 
pHR’SINcPPT-SEW_HLA-B*44:03 22.6 1511 537 
 
Generation of lentiviral vectors LV_GFP, LV_HLA-A*02:01 and LV_HLA-44:03 
Based on the protocol of Naldini et al. [147] lentiviral vectors were generated by co-
transfecting (1) pHR'SINcPPT-SEW / pHR'SINcPPT-SEW_HLA-A*02:01 / 
pHR'SINcPPT-SEW_HLA-B*44:03, (2) pCMV∆R8.91 and (3) pM.DG. To quantify 
lentiviral vector particles HIV-1 p24 expression was determined. The infectious titer 
was evaluated based on the integration and expression of the gene of interest after 
the transduction of 293T cells determined by real-time PCR. 
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Determination of the infectious titer of the lentiviral vectors LV_GFP, LV_HLA-
A*02:01 and LV_HLA-B*44:03 
DNA- and mRNA based titer were determined based on a real-time PCR assay, 
established according to Lizée et al., 2003 [144]. The integration of the gene of 
interest as well as the lentiviral expression of the gene of interest in transduced cells 
was analyzed. The integration was ensured by the detection of WPRE specific DNA, 
while the expression of the gene of interest was ensured by the detection of WPRE 
specific mRNA. Table 9.1 and 9.2 summarize albumin, β-actin and WPRE 
concentrations. Table 4.5 summarizes HIV-1 p24 concentrations and the calculated 
lentiviral vector titers. For the transduction of CD14+ monocytes a MOI of 1.5 was 
used (DNA-based titer). 
 
Table 4.5 DNA- and mRNA-based titer of lentiviral vectors: LV_GFP, LV_HLA-A*02:01 and 
LV_HLA-B*44:03 
Lentiviral vector 
DNA-based titer  
[TU / mL] 
 infectious particles 
mRNA-based titer 
[TU / mL] 
 mRNA expression 
Architect i2000SR  
[S / CO*] 
 p24 expression 
LV_GFP 3.88*108 1.56*106 1084.10 
LV_HLA-A*02:01 4.59*108 4.56*106 1226.01 
LV_HLA-B*44:03 3.18*108 8.36*106 1196.65 
* <1.00 nonreactive 
 
Determination of the protein content within lentiviral vectors: LV_GFP, LV_ HLA-
A*02:01 and LV_HLA-B*44:03 
The protein content of lentiviral vectors: LV_GFP, LV_HLA-A*02:01, LV_HLA-
B*44:03 and a control (untransfected 293T supernatant, microvesicle control) was 
determined using the Bradford protein assay and measuring absorbance at 595 nm. 
A standard curve was generated using known concentrations of BSA. Using the 
slope, protein contents of the lentiviral vectors and the negative control were 
calculated. Figure 4.4 shows the standard curve. 
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Figure 4.4 Standard curve generated by the measurement of known concentrations of BSA. 
The slope y=0.6205ln(x)-0.4072 is used to calculate the total protein concentration of lentiviral 
vectors and the negative control. 
 
Table 4.6 summarizes the calculated protein concentrations of each lentiviral vector. 
The control was used as the negative control in the transduction of CD14+ monocytes 
and was applied adjusted to the lentiviral vector protein content. 
 
Table 4.6 Calculated total protein concentrations of lentiviral vector stocks 
Lentiviral vector Absorbance (595 nm) 
Total protein concentration  
[µg / mL] 
LV_GFP 1.550 2026 
LV_HLA-A*02:01 1.654 2378 
LV_HLA-B*44:03 1.570 2089 
control (293T supernatant) 1.446 1727 
 
4.4 Generation of infectious recombinant HIV-1 ADA: ADA_V82A, ADA_L210F 
This part focuses on the generation of recombinant pADA-based HIV-1, including 
either the mutation V82A (PR) or L210F (RT). ADA is a well characterized laboratory 
HIV-1 strain, subtype B, macrophage-tropic [148]. 
 
Cloning of pADA-pol in pCR2.1®-TOPO®TA 
In order to generate recombinant pADA-based HIV-1, the pADA-pol region was 
cloned in the cloning plasmid pCR2.1®-TOPO®TA, resulting in the product pCR2.1®-
TOPO®TA-pol. The integration of pADA-pol was verified performing a restriction 
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digest of pCR2.1®-TOPO®TA-pol and the subsequent identification of products via 
gel electrophoresis (data not shown). 
 
Introduction of specific tRAMs (V82A and L210F) via SDM 
Specific tRAMs (V82A (PR) and L210F (RT)) were integrated in pCR2.1®-TOPO®TA-
pol via SDM. SDM products were transformed in JM109 for amplification. To 
characterize SDM clones, a PCR reaction was performed using the TOPO-5’ / 
TOPO-3’ primer set (table 2.4b), amplifying the pADA-pol ORF and visualizing via gel 
electrophoresis (data not shown).  
 
Cloning mutagenised pols (deriving from pCR2.1®-TOPO®TA-pol_V82A and 
pCR2.1®-TOPO®TA-pol_L210F) in pADA backbone 
To determine a successful integration of the different pADA-pol SDM products back 
in the pADA backbone, the respective plasmid DNA was isolated and a PCR was 
performed using primer HIV-pol-5’ and HIV-pol-3’ (table 2.4b) amplifying the pol ORF 
with a length of 1510 bp. The PCR product was visualized via gel electrophoresis as 
shown in figure 4.5. 
 
(A) 
 
MA  CA  NC  p6
PR      RT      IN
pol
gag
primer binding site:
HIV-pol-5'
primer binding site:
HIV-pol-3'
1510bp
 
(B) 
 
Figure 4.5 Determining the presence of pADA-pol back in pADA backbone using pol specific 
primer in a PCR. (A) Schematic overview of pADA and HIV-pol primer binding sites. (B) 
Identification of pADA-pol ORF using gel electrophoresis at 1510 bp. 
 
A sequencing reaction of SDM pADA-pol PCR products was performed to verify the 
presence of integrated tRAMs V82A (PR) and L210F (RT) using the ViroSeq® HIV-1 
Genotyping System. Sequences were edited and uploaded in geno2pheno (table 
2.13) to identify substitutions in PR and RT compared to the diagnostic reference 
strain HXB2. As the ADA HIV-1 strain is in this study used as reference, the 
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substitutions of pADA-pol were also analyzed. Table 4.7 summarizes all substitutions 
found for each clone, all differing at the respective amino acid positions, where the 
tRAMs were integrated. 
 
Table 4.7 Substitutions within pADA-pol SDM clones compared to HXB2 
SDM clones 
Substitution in PR (compared 
to HXB2 reference strain) 
Substitution in RT (compared 
to HXB2 reference strain) 
pADA-pol V3I, S37N, R57G 
K102Q, E122K, S162C, L214F, 
P272A, I293V 
pADA-pol_V82A V3I, S37N, V82A 
K102Q, E122K, L214F, P272A, 
I293V 
pADA-pol_L210F V3I, S37N 
K102Q, E122K, S162C, L210F, 
L214F, P272A, I293V  
 
Generation of infectious HIV-1 particles: ADA, ADA_V82A and ADA_L210F 
293T cells were transfected with pADA, pADA_V82A and pADA_L210F. Three days 
post transfection, the supernatant was used to infect PM-1 cells. Cells were observed 
using a light microscopy (figure 4.6) to detect CPE formation before harvesting viral 
particles on day four. 
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(A) (B) 
  
 
(C) 
 
(D) 
  
 
Figure 4.6 Light microscopic pictures (20x original magnification) of PM-1 cells infected or not 
with ADA, ADA_V82A and ADA_L210F on day four post infection. The arrows indicate CPE 
formation. (A) uninfected, (B) infected with ADA, (C) infected with ADA_V82A and (D) infected 
with ADA_L210F cells  
 
Determination of the infectious titer of ADA, ADA_V82A and ADA_L210F 
After the harvest, the number of the viral particles was determined measuring p24 
concentrations and viral copy numbers were detected using the RealTime HIV-1 
assay (table 4.8). However, in order to quantify the infectious units, CEMx174-M7R5-
EGFP-Luc cells were infected with serial dilutions of ADA, ADA_V82A, and 
ADA_L210F. CEMx174-M7R5-EGFP-Luc cells carry the reporter gene eGFP that is 
expressed in response to the HIV-1 tat protein. The infectious status of the cells was 
evaluated with respect to eGFP expression and the titer can be calculated using the 
Kärber equation [155]. Table 4.8 summarizes the number of viral particles and the 
infectious units for each viral strain. 
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Table 4.8 Summary of HIV-1 ADA infectious particles, p24 antigen expression and HIV-1 
integrase mRNA expression 
Viral Strain 
TCID50 / mL 
 infectious particles 
Architect i2000SR  
[S/CO*] 
 p24 expression 
m2000
TM 
copies / mL 
 mRNA expression 
of HIV-1 integrase 
ADA 1.17*105 829.03 6.09*107 
ADA_V82A 1.17*104 328.23 2.40*107 
ADA_L210F 1.17*106 1149.78 8.00*107 
* <1.00 nonreactive 
 
Determination of the protein content of the HIV-1 ADA stocks: ADA, ADA_V82A and 
ADA_L210F 
The protein contents of HIV-1 ADA: ADA; ADA_V82A, ADA_L210F and a control 
(uninfected PM-1 supernatant, microvesicle control) were determined using the 
Bradford protein assay and measuring the absorbance at 595 nm. According to a 
standard curve of known BSA concentrations (figure 4.4) protein concentrations of 
HIV-1 ADA and the negative control were calculated (table 4.9). The control was 
used as the negative control in the infection of moDCs and was applied, adjusted to 
HIV-1 ADA protein contents.  
 
Table 4.9 Calculated total protein concentrations of HIV-1 ADA stocks 
Viral strain Absorbance (nm) 
Total protein concentration  
[µg / mL] 
ADA 1.913 3540 
ADA_V82A 1.892 3428 
ADA_L210F 1.984 3939 
neg. control (PM-1 supernatant) 1.941 3696 
 
4.5 Establishment of a cell culture model to determine the innate and adaptive 
immune response 
The establishment of the cell culture model included the production of lentiviral 
vectors and the generation of recombinant moDCs, which over-express HLA alleles 
of interest. Recombinant moDCs were infected with recombinant HIV-1 (with RAMs in 
RT and PR). The supernatants of co-cultures with CD16+CD56+ NK and CD8+ T cells 
were analyzed for differences in cytokine and chemokine levels.  
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Purification of CD14+ monocytes 
In order to generate moDCs, CD14+ monocytes were purified from PBMCs of healthy 
donors. The number of PBMCs as well as the number of CD14+ monocytes varied 
highly between the different donors. The number of CD14+ monocytes decreased 
strongly from day one to day two. Table 4.10 summarizes the numbers of PBMCs, 
day one and day two CD14+ monocytes. Day two CD14+ monocytes were harvested 
for the transduction with lentiviral vectors. 
 
Table 4.10 Numbers of PBMCs and purified day one and day two CD14
+
 monocytes  
day 1 CD14
+
 monocytes day 2 CD14+ monocytes Healthy 
donor 
PBMCs 
total % of PBMCs Total % of PBMCs 
1 5,736,000,000 90,400,000 1.58 32,500,000 0.57 
2 7,441,500,000 63,200,000 0.85 22,500,000 0.30 
3 6,471,000,000 44,100,000 0.68 29,400,000 0.45 
4 3,573,000,000 67,200,000 1.88 26,200,000 0.73 
 
The morphology of day one CD14+ monocytes showed a spherical form with a grainy 
surface (figure 4.7 (A)). Adding GM-CFS and IL4 to the culture of CD14+ monocytes 
led to differentiation of cells. Day two CD14+ monocytes appeared elongated and 
started forming dendrite-like arms (figure 4.7 (B)).  
 
(A) (B) 
  
Figure 4.7 Light microscopic pictures (20x original magnification) of day one and day two 
CD14
+
 monocytes. Exemplarily, showing one donor out of four. (A) CD14
+
 monocytes on day 
one, (B) on day two. 
 
The quantity and quality of purified CD14+ monocytes was assessed, staining cells 
for CD3 and CD14 surface markers and flow cytometry. The maturation status was 
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monitored, staining cells for CD25, CD80, CD83, CD86 and HLA-DR (figure 4.8 / 
table 4.11).  
 
(A) (B) (C) 
   
(D) (E) (F) 
   
(G)   
 
  
Figure 4.8 Flow cytometric analysis of the quantity, quality and maturation status, using well 
characterized surface markers, of purified CD14
+ 
monocytes. Exemplarily, showing one donor 
out of four. (A) shows the percentage of CD3
+
 cells, (B) the percentage of CD14
+
 cells, (C) the 
CD25 maturation marker, (D) CD80, (E) CD83, (F) CD86 and (G) HLA-DR. The grey curves show 
the isotype control, whereas the blue curves represent the stained surface markers. 
 
The percentage of purified CD14+ monocytes ranged from 57.44 % to 91.3 % with a 
percentage of CD3+ cells of 1.21 % to 15.2 % between the different donors. No 
expression of CD25 and CD80 was detected and only little of CD83, indicating the 
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presence of immature CD14+ monocytes. CD86, a marker for early monocyte 
maturation, and HLA-DR were up-regulated. 
 
Table 4.11 Summary of the flow cytometry analysis of the quantity, quality and maturation 
status of purified CD14
+ 
monocytes 
Healthy donor 
Maturation marker 
1 2 3 4 
3.97 [0.994*] 15.2 [1.04*] 1.21 [0.94*] 1.88 [1.02*] CD3           % - T 
                  MFI (VioBlue) 5353 [6411*] 3051 [2688*] 128 [32*] 130 [207*] 
91.3 [1.02*] 89.8 [1.06*] 83.83 [1.04*] 57.44 [1.06*] CD14         % - T 
                  MFI (PE) 11600 [618*] 8048 [349*] 64 [6*] 105 [22*] 
1.78 [1.02*] 5.53 [1.06*] 3.07 [1.04*] 1.18 [1.06*] CD25         % - T 
                  MFI (PE) 592 [618*] 330 [349*] 9 [6*] 16 [22*] 
1.18 [1.02*] 5.56 [1.06*] 2.08 [1.04*] 1.26 [1.06*] CD80         % - T 
                  MFI (PE) 577 [618*] 335 [349*] 4 [6*] 25 [22*] 
12.4 [1.02*] 26.0 [1.06*] 28.69 [1.04*] 2.34 [1.06*] CD83         % - T 
                  MFI (PE) 1175 [618*] 984 [349*] 32 [6*] 21 [22*] 
94.2 [1.02*] 93.0 [1.06*] 70.56 [1.04*] 46.44 [1.06*] CD86         % - T 
                  MFI (PE) 1996 [618*] 1630 [349*] 29 [6*] 30 [22*] 
58.0 [1.06*] 85.4 [0.989*] 46.94 [0.99*] n.a. HLA-DR     % - T 
                  MFI (FITC) 1488 [1362*] 1982 [825*] 21 [22*] n.a. 
* neg. control 
 
Transducing CD14+ monocytes with the lentiviral vectors LV_ HLA-A*02:01 and 
LV_HLA-44:03 
Day two CD14+ monocytes were harvested for the transduction with lentiviral vectors 
LV_HLA-A*02:01 and LV_HLA-B*44:03 at a MOI of 1.5 (DNA-based titer). After 
transduction, on day four on day six of culture, the morphology of untransduced and 
LV-transduced cells was observed, all showed the typical dendrites. No differences 
could be noted between the morphology. Comparing cell viability, both untransduced 
and LV-transduced cells showed a reduction in cell number on day six (figure 4.9). 
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(A) (B) 
  
(C) (D) 
  
Figure 4.9 Light microscopic pictures (20x original magnification) of untransduced and LV-
transduced cells. Exemplarily, showing one donor out of four. (A) untransduced CD14
+
 
monocytes on day four, (B) moDCs on day six, (C) LV-transduced CD14
+
 monocytes on day 
four and (D) LV-transduced moDCs on day six. 
 
To verify the successful transduction of CD14+ monocytes, genomic DNA of day ten 
co-cultures, containing LV-transduced moDCs, was isolated. A real-time PCR was 
performed to detect WPRE, which integrates together with the genes of interest in 
transduced cells. 
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Figure 4.10 Real-time PCR amplification curves detecting integrated WPRE in moDCs of the 
four donors to conclude the transduction of CD14
+
 monocytes. 
 
Cycle numbers of amplification curves detecting WPRE were used to determine 
WPRE copy numbers (figure 4.10). The cell content of co-cultures containing 
transduced moDCs and CD16+CD56+ NK cells and CD8+ T cells was determined 
measuring the housekeeping gene albumin. In all of the co-cultures integrated WPRE 
could be detected in moDCs, verifying the transduction with lentiviral vectors (table 
4.12). Nevertheless, no conclusion could be drawn on the percentage of transduced 
CD14+ monocytes, as DNA was isolated of day ten co-cultures. 
 
Table 4.12 Cycle number of real-time amplification curves detecting WPRE, calculated WPRE 
copy numbers (according to standards) and the cell count determined by the detection of 
albumin 
Donor cycle number Calculated WPRE 
copy number 
Cell count (according 
to albumin 
concentrations) 
1 33.13 104 3560 
2 32.24 211 8700 
3 32.59 160 3905 
4 31.60 342 6750 
neg. control 35.00 20.7 2.73 
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Infection of LV-transduced moDCs with HIV-1 ADA_V82A and ADA_L210F 
On day six of culture, moDCs were infected with HIV-1 ADA_V82A and ADA_L210F, 
respectively, in order to analyze the effect of different HIV-1 ADA on moDCs. Prior to 
infection, no differences between the cell counts of moDCs could be observed, 
comparing untransduced and LV-transduced; indicating that lentiviral vectors did not 
have an impact on cell viability (table 4.13). 
 
Table 4.13 Numbers of untransduced and LV-transduced moDCs used for the infection with 
HIV-1 ADA_V82A and ADA_L210F of all donors 
Healthy donor Day 6 moDCs Day 6 LV-transduced moDCs 
 Total % of PBMCs total % of PBMCs 
1 2,600,000 0.05 2,850,000 0.05 
2 2,650,000 0.04 2,850,000 0.04 
3 1,950,000 0.03 1,800,000 0.03 
4 2,900,000 0.08 2,350,000 0.07 
 
Figure 4.11 shows the morphology of uninfected and HIV-1 ADA infected moDCs on 
day seven and eight. On day seven, no visible differences could be observed. 
However, while on day eight uninfected moDCs remain unchanged, HIV-1 ADA 
infected moDCs showed smaller roundish cells close by.  
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(A) (B) 
  
(C) (D) 
  
Figure 4.11 Light microscopic pictures (20x original magnification) of uninfected and HIV-1 
ADA infected moDCs. Exemplarily, showing one donor out of four and only one of the used 
HIV-1 ADA (HIV-1 ADA_V82A). (A) uninfected on day seven, (B) uninfected on day eight, (C) 
HIV-1 ADA infected on day seven and (D) HIV-1 ADA infected on day eight. 
 
Figure 4.12 shows in comparison to figure 4.11 LV-transduced moDCs. While no 
change in morphology could be observed between untransduced and LV-transduced 
moDCs on day seven, day eight cells showed spindle-like structures and smaller 
roundish shaped cells close by. No differences could be observed between day eight 
moDCs and the ADA infected LV-transduced moDCs of day seven and eight. 
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(A) (B) 
  
(C) (D) 
  
Figure 4.12 Light microscopic pictures (20x original magnification) of LV-transduced 
uninfected and HIV-1 ADA infected moDCs. Exemplarily, showing one donor out of four and 
only one of the used HIV-1 ADA (HIV-1 ADA_V82A) (A) uninfected on day seven, (B) uninfected 
on day eight, (C) HIV-1 ADA infected on day seven and (D) HIV-1 ADA infected on day eight. 
 
To verify the infection of moDCs, genomic DNA was isolated of day ten co-cultures of 
HIV-1 ADA infected moDCs and CD16+CD56+ NK cells and CD8+ T cells. The 
RealTime HIV-1 assay was performed to determine viral copy numbers.  
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(A) 
 
(B) 
 
Figure 4.13 Real-time PCR amplification curves determining the presence of HIV-1 integrase to 
verify the infection with HIV-1 ADA of moDCs. Exemplarily, showing one donor out of four (A) 
infection with ADA_V82A and (B) with ADA_L210F 
 
Amplification curves showed that moDCs were HIV-1 ADA infected. However, the 
percentage of infected moDCs could not be determined, as DNA was isolated from 
co-cultures, not only containing moDCs, but also CD16+CD65+ NK cells and CD8+ T 
cells. Figure 4.13 shows exemplarily donor 1 (the amplification curves of donor 2-4 
are shown in figure 9.2). Table 4.14 summarizes cycle numbers of real-time 
amplification curves detecting HIV-1 integrase of all four donors. 
 
Table 4.14 Cycle numbers of real-time amplification curves detecting HIV-1 integrase of all 
donors 
Donor moDCs infected with ADA_V82A  
 cycle number 
moDCs infected with ADA_L210F 
 cycle number 
1 25.15 25.74 
2 24.17 24.50 
3 24.46 24.59 
4 23.71 23.68 
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Purification of CD16+CD56+ NK cells and CD8+ T to co-culture with HIV-1 ADA 
infected LV-transduced moDCs 
On day eight of culture, CD16+CD56+ NK cells were purified from the negative 
fraction of CD14+ monocytes. In order to monitor the purification of CD16+CD56+ NK 
cells, cells were stained for CD16 and CD56 surface markers (figure 4.15). The 
percentage of cells expressing both CD16 and CD56 were quantified by the MFI of 
both fluorescent dyes labelling the antibodies. The dot plots show the population of 
CD16+CD56+ NK cells (figure 4.14). 
 
(A) (B) 
  
Figure 4.14 Flow cytometric analysis of the quantity and quality of purified CD16
+
CD56
+
 NK 
cells via flow cytometry. Exemplarily, showing one donor out of four. (A) isotype control as 
negative control, (B) CD16
+
CD56
+
 NK cells 
 
The percentage of CD16+CD56+ NK cells ranged from 73.6 % to 80.2 % (table 4.15) 
between the different donors. 
 
Table 4.15 Summary of flow cytometry results to analyze quantity and quality of purified 
CD16
+
CD56
+
 NK cells of all donors. 
CD16 FITC / CD56 PE 
Healthy donor 
% - T MFI (FITC) MFI (PE) 
1 77.9 [26.6*] 773 [196*] 833 [103*] 
2 80.2 [4.27*] 1658 [876*] 1781 [296*] 
3 32.9 [4.49*] 17.04 [4.96*] 15.53 [1.32*]  
4 73.6 [1.61*] 1999 [773*] 1367 [368*] 
* neg. control 
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Subsequently, CD8+ T cells were isolated from the negative fraction of CD16+CD56+ 
NK cells. The number of purified CD16+CD56+ NK cells ranged from 1.7*106 – 5*106 
cells, while the numbers of CD8+ T cells ranged from 48.1*106 – 90.3*106 cells. 
Comparing CD16+CD56+ NK cell and CD8+ T cell numbers, CD8+ T cells were 
present in much greater numbers (13.4 – 53.1 times higher). 
 
Table 4.16 Number of purified CD16
+
CD56
+
 NK and CD8
+
 T cells of all donors. 
Number of CD16
+
CD56
+
 cells Number of CD8
+
 cells Healthy donor 
Total % of PBMCs Total % of PBMCs 
1 1,700,000 0.03 90,250,000 1.57 
2 5,000,000 0.07 71,950,000 0.97 
3 2,900,000 0.04 48,050,000 0.74 
4 4,900,000 0.14 80,300,000 2.25 
 
Light microscopic pictures of figure 4.15 show the different cell morphologies of CD8+ 
T cells and CD16+CD56+ NK cells.  
 
(A) (B) 
  
Figure 4.15 Light microscopic pictures (20x original magnification) of (A) CD8
+
 T cells and (B) 
CD16
+
CD56
+
 NK cells. Exemplarily, showing one donor out of four. 
 
To monitor the purity of CD8+ T cells, cells were analyzed via flow cytometry staining 
for CD3 and CD8 surface markers (figure 4.16). 
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(A) (B) 
Figure 4.16 Flow cytometric analysis of the quantity and quality of purified CD8
+
 cells. 
Exemplarily, showing one donor out of four. The grey curves show the isotype control, 
whereas the blue curves represent the stained surface markers. (A) percentage of CD3
+
 cells, 
(B) percentage of CD8
+
 cells 
 
CD3+ cell counts ranged from 7.18 - 55.8 % and CD8+ T cells from 13.9 – 31.23 %. 
Table 4.17 summarizes cell counts of the different donors. 
 
Table 4.17 Summary of flow cytometry results to analyze quantity and quality of purified CD8
+
 T 
cells of all donors. 
anti-CD3 VioBlue anti-CD8 PerCP 
Healthy donor 
% - T MFI (VioBlue) % - T MFI (PerCP) 
1 47.8 [1.01*] 1142 [1376*] 28.2 [1.02*] 1733 [877*] 
2 55.8 [1.07*] 1037 [1166*] 26.1 [1.05*] 1620 [813*] 
3 39.24 [1.06*] 24.11 [8.65*] 31.23 [1.03*] 19.05 [14.16*] 
4 7.18 [1.01*] 3349 [3457*] 13.9 [1.02*] 627 [428*] 
*neg. control 
 
Co-culture of moDCs with either CD16+CD56+ NK or CD8+ T cells 
Untransduced and LV-transduced moDCs, either infected with HIV-1 ADA_V82A or 
ADA_L210F were, on day eight of culture, co-cultured with CD16+CD56+ NK or CD8+ 
T cells. The cell numbers of the different fractions of moDCs ranged from 50,000 to 
210,000 and are summarized in table 4.18. The number of co-cultured CD16+CD56+ 
NK and CD8+ T cells was adjusted accordingly and added in a 1:1 ratio.  
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Table 4.18 Summary of moDC numbers in the different cell fractions of all donors 
healthy donor 1 healthy donor 2 healthy donor 3 healthy donor 4 Cell 
fraction total # 
of 
cells 
% of 
PBMCs 
total # 
of 
cells 
% of 
PBMCs 
total # 
of 
cells 
% of 
PBMCs 
total # 
of 
cells 
% of 
PBMCs 
uninfected 9.5* 0.0017 8.5* 0.0011 5.0* 0.00077 21.0* 0.0059 
ADA_V82A 
infected 
12.5* 0.0022 10.5* 0.0014 6.5* 0.001 15.0* 0.0042 
ADA_L210F 
infected 
10.5* 0.0018 17.5* 0.0024 5.0* 0.00077 11.0* 0.0031 
LV-
transduced, 
uninfected 
5.5* 0.0009 13.0* 0.0017 6.5* 0.001 12.0* 0.0034 
LV-
transduced, 
ADA_V82A 
infected 
9.5* 0.0017 20.5* 0.0028 6.5* 0.001 15.0* 0.0042 
LV-
transduced, 
ADA_L210F 
infected 
13.0* 0.0023 15.5* 0.0021 6.0* 0.00093 15.0* 0.0042 
*104 
 
Differences between the cultures of untransduced and LV-transduced cells could be 
observed in the morphology of the co-culture of moDCs with CD16+CD56+ NK cells 
on day nine. Comparing light microscopic pictures of co-cultures of day nine and ten 
of moDCs with CD16+CD56+ NK cells, revealed an activation of CD16+CD56+ NK 
cells and the killing of moDCs. There was no visible difference between 
untransduced and LV-transduced cells nor between uninfected and HIV-1 ADA 
infected moDCs (figure 4.17). 
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(A) (B) 
  
 
(C) (D) 
  
 
(E) (F) 
  
 
(G)  (H)  
  
 
Figure 4.17 Light microscopic pictures (20x original magnification) of co-cultures of moDCs 
and CD16
+
CD56
+
 NK cells on day nine and ten. Exemplarily, showing one donor out of four. 
(A) moDCs on day nine, (B) moDCs on day ten, (C) LV-transduced moDCs on day nine, (D) LV-
transduced moDCs on day ten, (E) LV-transduced HIV-1 ADA_V82A moDCs on day nine, (F) 
LV-transduced HIV-1 ADA_V82A moDCs on day ten, (G) LV-transduced HIV-1 ADA_L210F 
moDCs on day nine and (H) LV-transduced HIV-1 ADA_L210F moDCs on ten. 
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Figure 4.18 shows pictures of co-cultures of untransduced and LV-transduced 
moDCs with CD8+ T cells on day nine and ten of culture. Light microscopic pictures 
of day ten showed no visible difference between uninfected untransduced and LV-
transduced cells. But observing HIV-1 ADA_V82A and ADA_L210F infected moDCs, 
one could see that CD8+ T cells accumulated. 
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(A)  (B)  
  
 
(C)  (D)  
  
 
(E)  (F)  
  
 
(G)  (H)  
  
 
Figure 4.18 Light microscopic pictures (20x original magnification) of co-cultures of moDCs 
and CD8
+
 T cells on day nine and ten. Exemplarily, showing one donor out of four. (A) moDCs 
on day nine, (B) moDCs on day ten, (C) LV-transduced moDCs on day nine, (D) LV-transduced 
moDCs on day ten, (E) LV-transduced HIV-1 ADA_V82A moDCs on day nine, (F) LV-
transduced HIV-1 ADA_V82A moDCs on day ten, (G) LV-transduced HIV-1 ADA_L210F moDCs 
on day nine and (H) LV-transduced HIV-1 ADA_L210F moDCs on ten. 
                                                                                                                                     RESULTS  
85 
Light microscopic pictures of co-cultures suggested the presence of dead cells. To 
determine whether co-cultures with CD8+ T or CD16+CD56+ NK cells contain more 
dead cells, untransduced and LV-transduced moDCs, co-cultured with either 
CD16+CD56+ NK cells or CD8+ T cells, were stained with propidium iodide, which 
enters porous cells and intercalates with the DNA. Figure 3.19 shows histograms 
indicating the percentage of dead cells. 
 
(A)  (B)  
  
(C)  (D)  
Figure 4.19 Flow cytometric analysis of the cell viability in co-cultures of moDCs / CD8
+
 T cells 
and moDCs / CD16
+
CD56
+
 NK cells. The grey curves show the isotype control, whereas the 
blue curves represent the stained surface markers. (A) co-culture of moDCs and CD16
+
CD56
+
 
NK cells, (B) co-culture of LV-transduced moDCs and CD16
+
CD56
+
 NK cells, (C) co-culture of 
moDCs and CD8
+
 T cells, (D) co-culture of LV-transduced moDCs and CD8
+
 T cells 
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Table 4.19 summarizes the data of %-T and MFI (PE) of propidium iodide stained 
cells, indicating the amount of dead cells. Co-cultures containing CD16+CD56+ NK 
cells contained between 23.5 – 26.4 % dead cells, whereas co-cultures with CD8+ T 
cells contained 10.3 – 14.5 % . The amount of dead cells within co-cultures 
containing CD16+CD56+ NK cells was significantly higher than in CD8+ T cells (p = 
0.0389). 
 
Table 4.19 Summary of flow cytometry results to analyze cell viability in co-cultures of moDCs / 
CD8
+
 T cells and moDCs / CD16
+
CD56
+
 NK cells 
co-culture %-T MFI (PE) 
moDCs / CD16+CD56+ NK cells 23.5 1842 
LV-transduced moDCs / CD16+CD56+ NK cells 26.4 2074 
moDCs / CD8+ T cells 14.5 2587 
LV-transduced moDCs / CD8+ T cells 10.3 2568 
neg. control 0.998 1150 
 
Determination of the cytokine and chemokine release in HIV-1 infected patients 
The killing of infected cells by CD16+CD56+ NK cells and CD8+ T cells requires 
signaling between infected cells and effector cells for their differentiation and 
activation. This process can be executed by the secretion of cytokines and 
chemokines, and their binding to specific receptors and the activation of underlying 
signaling cascades.  
In a first step, the cytokine and chemokine release associated with HIV-1 infection 
was determined. Here for, a cohort of patients with low (< 50, therapy-experienced) 
and high (> 500,000, therapy-naïve) plasma viral load (pVL) was analyzed for the 
release of cytokines and chemokines and was compared with healthy donors. 
Significant differences could surprisingly be observed both, between HIV-1 infected 
patients with low pVL and healthy donors and patients with high pVL and healthy 
donors. Levels of the cytokines IL-2R (p = 0.00776) and IL-12 (p = 0.00011) and the 
chemokines CCL2 (p = 0.00357), CCL11 (p = 0.00026), CXCL9 (p = 0.00017) and 
CXCL10 (p = 0.00045) were significantly elevated in HIV-1 infected patients with high 
pVL. In addition, in HIV-1 infected patients with pVL under the limit of detection (pVL 
< 50), levels of the cytokines IL-1β (p = 0.01831), IL-1RA (p = 0.02746), IL-2R (p = 
0.00011), IL-4 (p = 0.00112), IL-8 (p = 0.01928), IL-13 (p = 0.02977), IL-15 (p = 
0.03651), IL-17 (p = 0.00284) and TNF-α (p = 0.02118) were unexpectedly 
significantly lower than compared to the negative controls (figure 4.20). Levels of 
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IFN-γ and CCL5 were out of the upper and lower limit of detection, respectively and 
therefore not shown. 
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(A) 
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(B)  
 
Figure 4.20 Evaluation in plasma of HIV-1 infected and uninfected (black bar, n = 9) individuals 
for (A) cytokine and (B) chemokine secretion. HIV-1 infected patients were classified in 
patients with pVL under the limit of detection (pVL< 50 (therapy-experienced), blue bar, n = 40) 
and pVL > 0.5*10
6
 copies mL
-1
 ((therapy-naïve), red bar, n = 10). Asterisks show significant 
associations between the uninfected individuals and HIV-1 infected. 
 
Influence of the infection of moDCs with HIV-1 ADA_V82A and ADA_L210F on the 
cytokine and chemokine release of moDCs 
MoDCs were, on day six of culture, infected with HIV-1 ADA_V82A and ADA_L210F 
at 105 TCID50 / 10
6 cells. The effect of infection on the secretion of cytokines and 
chemokines was analyzed, determining levels on day two of culture and day eight, 
before the co-culture with either CD16+CD56+ NK cells or CD8+ T cells. Secretion 
upon infection with ADA_V82A and ADA_L210F was observed separately, and data 
were compared to the cytokine and chemokine secretion of uninfected cells. In 
various cases no differences in cytokine and chemokine release could be observed 
between uninfected and HIV-1 ADA infected moDCs, these cytokines include IFN-γ, 
IL-2, IL-5, IL-10, IL-13, IL-17 and the chemokines CCL11 and CXCL9. However, 
slightly elevated levels were determined in uninfected moDCs compared to HIV-1 
ADA infected cells, observing the cytokines IL-4, IL-7, IL-15, TNF-α and the 
chemokines CCL2, CCL4 and CCL5. Cytokines GM-CSF, IL-1β, IL-12 and 
chemokine CXCL10 showed the least secretion in HIV-ADA_V82A infected cells, 
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uninfected and ADA_L210F infected moDCs showed similar slightly elevated levels. 
Contrary, cytokine IL-2R and the chemokine CCL3 showed the least secretion when 
infected with HIV-1 ADA_L210F and slightly elevated levels after infection with 
ADA_V82A and in uninfected cells. Levels of cytokines IL-1RA and IL-6 remained low 
in uninfected and HIV-1 ADA_L210F infected moDCs, but are elevated in ADA_V82A 
infected cells. Cytokines IFN-α and IL-8 showed elevated levels, in HIV-1 ADA_V82A 
and ADA_L210F moDCs, respectively, compared to uninfected moDCs. None of 
these differences reached significance (figure 4.21). 
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(A)  
(B)  
Figure 4.21 (A) cytokine and (B) chemokine secretion of day two CD14
+
 monocytes (blue, 
mock) and day eight HIV-1 ADA infected moDCs (HIV-1 ADA_V82A, red; ADA_L210F, green).   
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Influence of the transduction of CD14+ monocytes on the cytokine and chemokine 
release of moDCs 
Before the infection of moDCs with HIV-1 ADA on day six of culture, day two CD14+ 
monocytes were transduced with LV_HLA-A*02:01 and LV_HLA-B*44:03, 
respectively at MOI 1.5 (DNA-based titer). To determine an impact of LV-transduction 
on cytokine and chemokine release, their secretion was determined before the 
transduction of CD14+ monocytes as well as on day eight of moDCs, before the co-
culture with either CD16+CD56+ NK cells or CD8+ T cells. In most cases, no 
differences in cytokine and chemokine release could be observed between 
untransduced and LV-transduced cells, these cytokines include IFN-γ, IL-1β, IL-2, IL-
5, IL-10, IL-13, IL-17, TNF-α and the chemokines CCL11, CXCL9 and CXCL10. 
However, slightly higher levels of the cytokines IL-1RA, IL-6, IL-12 and the 
chemokine CCL5 could be detected in LV-transduced cells (figure 4.20), while the 
amounts of the cytokines GM-CSF, IFN-α, IL-2R, IL-4, IL-7, IL-15 and the 
chemokines CCL2, CCL3 and CCL4 were elevated in untransduced cells (figure 
4.22). None of these differences reached significance. 
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(A)  
 
(B)  
 
Figure 4.22 (A) cytokine and (B) chemokine release detected in the supernatant of un-
transduced (blue) and LV-transduced (red) day two CD14
+
 monocytes and day eight moDCs. 
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Determination of cytokine and chemokine release in the co-culture of HIV-1 ADA 
infected moDCs with either CD16+CD56+ NK cells or CD8+ T cells indicating an 
immune escape of V82A (PR) or L210F (RT) in the respective HLA backgrounds 
The effect of HIV-1 ADA_V82A and ADA_L210F on cytokine and chemokine release 
was determined in co-cultures of moDCs deriving from either HLA-A*02:01 or HLA-
B*44:03 donor, with CD16+CD56+ NK cells and CD8+ T cells, respectively. Prior to 
infection, lentiviral vectors were used to introduce HLA-B*44:03 in the HLA-A*02:01 
donors and HLA-A*02:01 in the HLA-B*44:03 donors. 
It was assumed, that moDCs deriving from an HLA-A*02:01 positive donor can 
modify their cytokine and chemokine release upon encountering HIV-1 ADA_L210F, 
resulting either in an increase of release, or a decrease. V82A (PR) was identified as 
a possible immune escape mutation in the background of HLA-A*02:01. In this HLA 
background, an infection with HIV-1 ADA_V82A should modify cytokine and 
chemokine secretion less than detected for infections with ADA_L210F. Introducing 
HLA-B*44:03, using a lentiviral vector, into CD14+ monocytes deriving from HLA-
A*02:01 positive donors, should have no impact on cytokine and chemokine levels 
upon infection with HIV-1 ADA_V82A. However, as L210F (RT) has been described 
to be an immune escape mutation in the background of HLA-B*44:03, infection with 
HIV-1 ADA_L210F should result in a less pronounced secretion profile.  
Vice versa, moDCs of HLA-B*44:03 positive donor should show a modified cytokine 
and chemokine secretion pattern encountering HIV-1 ADA_V82A and less 
pronounced when infected with ADA_L210F. In transduced moDCs, introducing HLA-
A*02:01, the infection with either ADA_V82A or ADA_L210F should have no effect on 
cytokine and chemokine levels. 
In order to determine the impact of immune escape mutations, V82A (PR) and L210F 
(RT), cytokine and chemokine release in the co-cultures of HIV-1 ADA infected 
moDCs with either CD16+CD56+ NK cells or CD8+ T cells was analyzed. To cover a 
broad range of cytokines and chemokines, the human 25-plex panel was used. In 
general, the presence of either CD16+CD56+ NK cells or CD8+ T cells in moDC 
cultures resulted in higher levels of cytokine and chemokine release on day ten, 
compared to the absence on day eight. Independent of infection, an increase of 
cytokines and chemokines can be observed, comparing untransduced and LV-
transduced cells. 
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With respect to HLA-A*02:01 positive donors, co-cultures of moDCs and 
CD16+CD56+ NK cells showed the release of cytokines IL-4, IL-7, IL-8, IL-12 and IL-
15 as well as the chemokines CCL2, CCL4 and CCL5 (figure 4.23) according to 
model A2 (ratio ADA_L210F : ADA_V82A < 1 / ratio ADA_L210F : ADA_V82A ≥ 1, 
figure 1.8). Regarding, HLA-B*44:03 positive donor, co-cultures of moDCs and 
CD16+CD56+ NK cells showed the release of the cytokines IL-8 and IL-15 and the 
chemokines CCL2 and CCL3 (figure 4.24) according to model B2 (ratio ADA_V82A : 
ADA_L210F < 1 / ratio ADA_V82A : ADA_L210F ≥ 1, figure 1.8). Cytokines IL-4, IL-7 
and the chemokine CCL4 (figure 4.24) were secreted according to model B1 (ratio 
ADA_V82A : ADA_L210F > 1 / ratio ADA_V82A : ADA_L210F ≤ 1, figure 1.8).  
With respect to HLA-A*02:01 positive donors, co-cultures of moDCs and CD8+ T cells 
showed the release of cytokines IL-6, IL-7 and IL-8 as well as the chemokine CXCL9 
(figure 4.25) according to model A2 (ratio ADA_L210F : ADA_V82A < 1 / ratio 
ADA_L210F : ADA_V82A ≥ 1, figure 1.8).  
Regarding, HLA-B*44:03 positive donor, co-cultures of moDCs and CD8+ T cells 
showed the release of the cytokines IL-1RA, IL-7, IL-8 and the chemokines CCL2 
and TNF-α (figure 4.26) according to model B2 (ratio ADA_V82A : ADA_L210F < 1 / 
ratio ADA_V82A : ADA_L210F ≥ 1, figure 1.8). Chemokine CXCL9 was secreted 
according to model B1 (ratio ADA_V82A : ADA_L210F > 1 / ratio ADA_V82A : 
ADA_L210F ≤ 1, figure 1.8). 
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Figure 4.23 Fold difference in cytokine and chemokine release normalized to untransduced 
uninfected moDCs and transduced uninfected moDCs of HLA-A*02:01 in the absence (day 
eight, red) and presence of CD16
+
CD56
+
 NK cells (day ten, blue). Differences between cytokine 
and chemokine release upon encountering the two viral strains were calculated, dividing the 
fold differences of cytokine and chemokine release upon infection with ADA_L210F by the fold 
differences of cytokine and chemokine release upon infection with ADA_V82A. 
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Figure 4.24 Fold difference in cytokine and chemokine release normalized to untransduced 
uninfected moDCs and transduced uninfected moDCs of HLA-B*44:03 in the absence (day 
eight, red) and presence of CD16
+
CD56
+
 NK cells (day ten, blue). Differences between cytokine 
and chemokine release upon encountering the two viral strains were calculated, dividing the 
fold differences of cytokine and chemokine release upon infection with ADA_V82A by the fold 
differences of cytokine and chemokine release upon infection with ADA_L210F. 
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Figure 4.25 Fold difference in cytokine and chemokine release normalized to untransduced 
uninfected moDCs and transduced uninfected moDCs of HLA-A*02:01 in the absence (day 
eight, red) and presence of CD8
+
 T cells (day ten, blue). Differences between cytokine and 
chemokine release upon encountering the two viral strains were calculated, dividing the fold 
differences of cytokine and chemokine release upon infection with ADA_L210F by the fold 
differences of cytokine and chemokine release upon infection with ADA_V82A. 
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Figure 4.26 Fold difference in cytokine and chemokine release normalized to untransduced 
uninfected moDCs and transduced uninfected moDCs of HLA-A*02:01 in the absence (day 
eight, red) and presence of CD8
+
 T cells (day ten, blue). Differences between cytokine and 
chemokine release upon encountering the two viral strains were calculated, dividing the fold 
differences of cytokine and chemokine release upon infection with ADA_V82A by the fold 
differences of cytokine and chemokine release upon infection with ADA_L210F. 
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In summary, co-cultures of moDCs and CD16+CD56+ NK cells showed a differential 
secretion of IL-4, IL-7, IL-8, IL-15 and CCL4. While, the levels of IL-4, IL-7 and CCL4 
is decreased in HLA-A*02:01 positive donors with an introduced HLA-B*44:03 upon 
infection with HIV-1 ADA_L210F, the secretion of IL-4, IL-7 and CCL4 is increased in 
HLA-B*44:03 positive donors with an introduced HLA-A*02:01 upon infection with 
HIV-1 ADA_V82A. The secretion of IL-15 and IL-8 is decreased in the two above 
described settings, pointing to a possible involvement of V82A (PR) and L210F (RT) 
in their respective HLA-background, in immune escape. Co-cultures of moDCs and 
CD8+ T cells showed a differential secretion of IL-7, IL-8 and CXCL9. CXCL9 is 
decreased in HLA-A*02:01 positive donors with an introduced HLA-B*44:03 upon 
infection with HIV-1 ADA_L210F and increased in HLA-B*44:03 positive donors with 
an introduced HLA-A*02:01 upon infection with HIV-1 ADA_V82A. In contrast, the 
secretion of IL-7 and IL-8 is decreased in the two above described settings and again 
could be involved in an immune escape. 
Therefore, investigating immune escape, a reduction in the secretion of IL-7, IL-8 and 
IL-15 seems to be of importance. 
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5. Discussion 
The initiation and selection of treatment for therapy-naïve patients is based on 
several aspects. There are not only HIV-1 plasma viral load (pVL) and CD4+ T cell 
count to consider but also personal issues, like co-morbidities and likelihood of 
adherence. This work focuses on the consideration of the patients’ HLA-alleles for 
therapy selection.  
The host immune system is an important factor in the selection of mutations, causing 
the virus to adapt to the HLA type of the infected individual. The persistence of these 
mutations in a new host after transmission is influenced by the HLA alleles of the new 
host. If the relevant HLA allele, responsible for the selection of the mutation, is 
shared by donor and recipient, a reversion may not occur [157]. In general, mutations 
persist when they do not cause high viral fitness costs, because even minor 
enhancements in fitness can quickly lead to the replacement of less fit variants. 
Eventually high fitness costs can be overcome by additional compensatory 
mutations. Otherwise the reversion to the wild type sequence is most likely [158-162]. 
Several studies propose an adaptation of HIV-1 to common HLA alleles even on 
population level. These commonly found HLA alleles can shape the virus, leaving a 
genetic footprint of immune response, which could even influence the virus evolution 
leading to the replacement of the consensus sequence [133, 158, 162]. 
Mutations which are associated with resistances against certain drugs can possibly 
be located within HLA class I restricted epitopes. They can positively or negatively 
influence immunogenicity by hampering the binding of viral peptides to the restricting 
HLA class I allele, changing T cell recognition sites or altering peptide processing by 
the cellular proteasome [130-140]. This can possibly explain the persistence of 
transmitted drug resistance mutations (tRAMs) within the drug-free environment of 
about 10 % of the therapy-naïve patients of the RESINA study cohort. 
A standard antiretroviral therapy without the consideration of HLA-allele mediated 
immune selection could include antiretroviral drugs that would promote a therapy 
failure by providing a selective pressure for tRAMs, conferring not only resistance to 
the drug but also immune escape. The consideration of the host immune response is 
especially important in the treatment of therapy-naïve patients already harbouring 
tRAMs. In these patients the treatment should be optimized using all available 
information regarding virus and host to facilitate a long lasting therapy success. 
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In order to identify the direct clinical impact of tRAMs and the individual HLA type on 
the antiretroviral regimen and therefore therapy outcome and progression of disease, 
a cell culture model was established.  
This model allowed the study of immune function in the context of the whole viral 
particle and defined HLA alleles, independent of patient samples but still close to the 
in vivo environment. Previous work [163, 164] was based on ELISPOT (enzyme 
linked immuno spot) assays which however hold several disadvantages. ELISPOT 
assays depend on patients’ blood samples which contain depending on the status of 
HIV-1 infection, very low cell numbers. Assays could occasionally not be evaluated. 
In addition, ELISPOT assays were based on PBMCs, making it impossible to observe 
the behaviour of single cell types. Consequently, in the cell culture model established 
in this work, distinct cell types were purified before their use in culture. The 
stimulation of PBMCs in ELISPOT assays was accomplished using several peptides 
comprising viral epitopes, allowing the study of presentation and recognition of viral 
peptides only. In the cell culture model, the use of whole viral particles, however, 
allowed the study of the influence of mutations on peptide processing by the cellular 
proteasome. IFN-γ was the only marker evaluated in ELISPOT assays. Nevertheless, 
literature suggests the involvement of several cytokines and chemokines in the innate 
and adaptive immune responses of HIV-1 infected patients [165-167].  
To understand a possible association of cytokine / chemokine secretion and HIV-1 
infection, a cohort of patients with low (therapy-experienced) and high pVL (therapy-
naïve) was chosen to analyze cytokine and chemokine levels. Herefore the luminex 
assay was used, which is a high throughput method, facilitating the analysis of 25 
different cytokines and chemokines from each sample. Levels of IL-2R, IL-12, CCL2, 
CCL11, CXCL9 and CXCL10 were significantly elevated in patients with high pVL, 
while levels of IL-1β, IL-1RA, IL-2R, IL-4, IL-8, IL-13, IL-15, IL-17 compared to 
healthy individuals and TNF-α were significantly lower in patients with low pVL. 
Unfortunately, detected levels of IFN-γ were out of the upper limit of detection. 
Published data investigating cytokine and chemokine secretion usually do not 
distinguish between different pVL of HIV-1 infected patients, but rather aim at the 
identification of cytokines and chemokines, which are associated with early HIV-1 
infections or a progression of disease. Nevertheless, in early HIV-1 infection and 
during disease progression, HIV-1 infected patients show most likely high pVL. 
Literature data can, therefore, be compared to cytokine and chemokine secretion in 
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patients with high pVL of the here described cohort. Byrnes et al. described 
increased levels of IL-12 in early HIV-1 infection [168], whereas associations of IL-2R 
[169, 170], CCL2 [171], CXCL9 and CXCL10 [172, 173] with disease progression 
have been published.  
The previous work, based on ELISPOT assays and the investigation of the secretion 
of cytokines and chemokines in HIV-1 infected patients, guided to the development of 
the here established cell culture model. 
Starting with the assessment of significant associations between HLA class I alleles 
and HIV-1 tRAMs, possible immune escape mutants among tRAMs were identified. 
In total, nine associations were significant after correction for multiple testing. Of 
those nine associations, V82A (PR) which was in this study highly significantly 
associated with HLA-A*02:01, has also been found of significant high prevalence in 
the background of HLA-A*02:01 in another study, investigating 492 treated patients 
[174]. It is usually difficult to compare data of association studies between different 
patient cohorts, due to strong differences in the genetic background of patients. Even 
comparing associations found in this study and a patient cohort in Erlangen, 
Germany was not fully successful [175]. 
The in silico obtained results were used as the basis for the cell culture model: HLA 
alleles of interest (HLA-A*02:01 and HLA-B*44:03) were over-expressed on 
monocyte-derived DCs (moDCs), representing the most important antigen presenting 
cell type [176, 177]. A VSV-G-pseudotyped lentiviral vector system was chosen to 
ensure (1) the delivery of the gene of interest independent of receptor interaction and 
(2) a stable integration and expression of the gene of interest in these non-dividing 
cells. Lentiviral vectors were generated, carrying the two different HLA ORFs of 
interest, aiming at their delivery into moDCs to generate recombinant moDCs. These 
recombinant moDCs were later on infected with HIV-1 carrying tRAMs in RT and PR 
(V82A (PR) and L210F (RT)) to determine changes in immunogenicity. 
Immunogenicity was here investigated by observing changes in cytokine and 
chemokine release in the co-cultures of CD16+CD56+ NK cells or CD8+ T cells and 
recombinant moDCs.  
Several methods have been described to deliver genes into target cells. The 
transfection of CD14+ monocytes using naked DNA has not been described. Instead, 
introducing genes into target cells using viruses as carrier are common [147, 178-
180]. Here, target cells were CD14+ monocytes, which are non-dividing cells, 
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requiring the integration of the HLA ORF using lentiviral vectors. Lentiviral vectors 
have the ability to integrate their genome into non-dividing cells. The viral genome, 
including the gene of interest, in form of RNA is reverse-transcribed, when entering 
the target cells [147]. Proviral DNA is then inserted into the cellular genome at a 
random position, having the disadvantage that the site of integration is unpredictable 
and function of cellular genes could be impaired [181, 182]. 
Lentiviral vectors were pseudotyped with VSV-G to enable a transduction of CD14+ 
monocytes via endocytosis. In general, pseudotyping with VSV-G has the 
advantages to interact with a ubiquitous receptor on cells, giving the vector a broad 
host-cell range and in addition ensures lentiviral vector stability [183].  
The aim of this study included the generation of immature recombinant moDCs over-
expressing HLA alleles of interest, which were able to process and present HIV-1 
peptides on their cell surface. For this purpose, CD14+ monocytes were transduced 
with lentiviral vectors, at a preferred MOI (multiplicity of infection) of 1.5 to have a 
relatively high transduction efficacy, but at the same time, not causing maturation of 
CD14+ monocytes. Immature moDCs are specialized for antigen uptake, but can, 
upon appropriate stimuli, terminally differentiate into mature moDCs. Mature moDCs 
are enrolled in T cell recruitment [178]. Breckpot et al. described a percentage of 
transduced moDCs of 32.3 ± 11.8 % at a MOI of 1.5. Transduction at MOIs of 15 and 
150 increased transduction efficacies to 80.3 ± 11.5 % and 93.0 ± 2.8 %, but at the 
same time increased the expression of surface markers CD25, CD80, CD83, CD86, 
HLA class I and II [180]. However, in this study, the maturation status of moDCs was 
not followed investigating the expression of cell surface markers, due to small cell 
numbers. Instead, the release of cytokines and chemokines was determined in 
response to LV-transduction. Higher levels of the cytokines IL-1RA, IL-6, IL-12 and 
the chemokine CCL5 could be detected in LV-transduced cells. Nevertheless, this 
elevation was not significant and needs to be further evaluated.  
In addition, the influence of HIV-1 ADA infection of moDCs on cytokine and 
chemokine secretion was investigated. For the release of several cytokines and 
chemokines no differences could be observed between uninfected and HIV-1 ADA 
infected moDCs. This finding is in accordance with literature, HIV-1 does not cause 
maturation of moDCs [178].  
These results lead to the conclusion that neither LV-transduction, nor the infection 
with HIV-1 seemed to have a significant impact on viability and cytokine and 
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chemokine secretion of moDCs. Investigating co-cultures of moDCs with either 
CD16+CD56+ NK cells or CD8+ T cells, cell morphologies showed that co-cultures 
rapidly accumulated high numbers of dead cells. Quantification of dead cells in both 
co-cultures staining with propidium iodide, revealed a significantly higher percentage 
in co-cultures with CD16+CD56+ NK cells than with CD8+ T cells. This suggests a 
more rapid response of CD16+CD56+ NK cells than by CD8+ T cells upon 
encountering moDCs. CD16+CD56+ NK cells are highly cytotoxic and play a major 
role in the innate immune response and they provide rapid responses to viral 
infection [184, 185] Activation of these cells does not necessarily require activating 
signals, but is also executed by missing self-antigens caused by a down-regulation of 
HLA class I molecules [186, 187]. In contrast, CD8+ T cells form part of the adaptive 
immune response, but can also induce the cell death of virally infected cells [160, 
188]. Activation of CD8+ T cells is dependent on two separate signals the antigen, 
which is bound to HLA class I molecules, and a secondary signal that can be either 
CD80 or CD86 [189]. There are several ways to induce cell death of virally infected 
cells by CD16+CD56+ NK and CD8+ T cells. The best known mechanisms are the 
secretion of cytotoxins such as perforin and granzyme and the engagement of death 
receptors (CD95 / CD95 ligand) [111, 190, 191]. However, these mechanisms require 
cell to cell interactions of HIV-1 infected moDCs and CD16+CD56+ NK cells or CD8+ 
T cells. This can be facilitated by the secretion of cytokines and chemokines.  
An impairment of the secretion of cytokines and chemokines is most likely involved in 
immune escape mechanisms [192]. In this study, the impact of the putative immune 
escape mutation V82A (PR) in the background of HLA-A*02:01 on cytokine and 
chemokine secretion was evaluated and compared to cytokine and chemokine levels 
detected investigating the already described immune escape variant L210F (RT) in 
the background of HLA-B*44:03. Co-cultures of CD16+CD56+ NK cells or CD8+ T 
cells with moDCs infected with HIV-1 ADA_V82A and ADA_L210F, respectively, 
were analyzed for cytokine and chemokine secretion. An impairment of such 
secretion was detected for the cytokines IL-7, IL-8 and IL-15, which could be 
associated with immune escape. The infection with the viral strain, comprising the 
putative immune escape mutation V82A (PR) in the respective HLA background, led 
to similarly decreased levels of these three cytokines compared to L210F (RT). While 
levels of cytokine IL-8 were decreased within co-cultures of moDCs with 
CD16+CD56+ NK cells and CD8+ T cells, decreased levels of IL-7 could only be 
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detected in co-cultures with CD8+ T cells and decreased levels of IL-15 in co-cultures 
with CD16+CD56+ NK cells. 
IL-8 has been described to be enhanced in the peripheral blood and lymphoid tissue 
of HIV-1 infected patients, indicating an importance of this cytokine in disease [193]. 
It is an important pro-inflammatory cytokine with chemoattractant functions and can 
be secreted by a variety of cells, inducing not only the migration of neutrophils but 
also causing the respiratory burst [194]. In this study, patients with high pVL (therapy-
naïve) show high levels of IL-8 compared to healthy controls. Elevated plasma levels 
of pro-inflammatory cytokines, such as the here described IL-8 can be detected in 
untreated, chronic HIV-1 infections and are accompanied by an increase of virus 
transcription and possibly also the activation of transcription from latently infected 
cells [195]. Investigating HIV-1 infected patients with low (therapy-experienced) pVL, 
levels of IL-8 were significantly lower compared to healthy controls. In literature the 
impact of treatment on immune activation and thereby on cytokine and chemokine 
release is discussed controversially. While for some cytokines and chemokines a 
significant reduction of release below levels in healthy controls was described, levels 
of the same cytokine / chemokine remain above or are equal in patients under 
treatment compared to healthy controls in other studies including this work [171, 
196]. Nevertheless, an overall reduction of the overwhelming immune activation has 
been shown to be related to decreased pVL achieved by antiretroviral treatment, 
indicating a correlation between cytokine and chemokine secretion and pVL [171, 
197]. Not only IL-8 has been described to be elevated in HIV-1 infected patients, also 
IL-7 levels have been found to be increased [198]. IL-7 is a cytokine involved in the 
homeostasis of T cells, playing a role in the development, function, proliferation, and 
survival of CD8+ T cells [199]. It can be produced not only by dendritic cells, but also 
by lymphocytes and its disrupted signalling has been shown to result in impaired 
immunity [200]. In this study, infected patients with low pVL showed lower levels of 
IL-7 compared to healthy controls. In contrast, patients with high pVL showed high 
levels of IL-7. IL-15 has been found to be associated with viremia in primary HIV-1 
infection, with a rapid elevation in plasma levels [201]. It is a specific maturation 
factor for NK cells and can function as a NK cell survival factor [202]. In this study, 
investigating HIV-1 infected patients with low and high pVL, levels of IL-15 were 
significantly lower in patients with low pVL compared to healthy controls. In contrast, 
patients with high pVL showed high levels of IL-15. 
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In conclusion, the results of this study suggest that monitoring levels of IL-7, IL-8 and 
IL-15 could be beneficial investigating the activation of immune responses with 
respect to HIV-1 immune escape mutations.  
Analyzing the influence of the so far not investigated putative immune escape 
mutations associated with different HLA alleles could strengthen the role of IL-7, IL-8 
and IL-15 as potential biomarkers. Another interesting aspect to proof the role of IL-7, 
IL-8 and IL-15 as biomarkers would be translating findings back into patients. Plasma 
samples deriving from patients with relatively high pVL could be analyzed for a 
decrease in the secretion of IL-7, IL-8 and IL-15 indicating a putative immune escape 
in the restricting HLA background. 
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6. Abstract 
Understanding host-specific innate and adaptive immune responses in therapy-naïve 
HIV-1 infected patients is of high importance. In a drug-free environment, the immune 
system is the most dominant factor shaping the evolution of HIV-1. Mutations can be 
selected, causing the adaption of the virus to the HLA alleles of the infected 
individuals, negatively influencing the immunogenicity of epitopes. However, in 
treatment-experienced patients, the most dominant factors influencing viral evolution 
are antiretroviral drugs. As a consequence, drug resistance associated mutations 
(RAMs) within targeted HIV-1 proteins can evolve which can be transmitted (tRAMs) 
from one individual to another, resulting in the finding of 10 % of persisting tRAMs in 
therapy-naïve patients. It is assumed, that such a persistence of tRAMs in therapy-
naïve patients is influenced by the HLA alleles of the new host and that persisting 
tRAMs are most likely located within HLA class I restricted epitopes, leading to 
immune escape.  
Interactions of immune system and antiretroviral treatment could especially be 
important in the treatment of therapy-naïve patients already harbouring tRAMs. The 
consideration of HLA allele mediated immune selection could exclude antiretroviral 
drugs promoting a therapy failure by providing a selective pressure for tRAMs 
conferring not only resistance to the drug but also immune escape. Treatment could 
be optimized using all available information regarding virus and host to facilitate a 
long lasting therapy success. 
In this work, a statistical analysis was performed using Fishers exact test and 
correcting for multiple testing, identifying nine significant associations between 
protease inhibitor (PI), nucleoside reverse transcriptase inhibitor, non-nucleoside 
reverse transcriptase inhibitor tRAMs, found in a cohort of 139 therapy-naïve HIV-1 
infected patients and the patients’ HLA alleles.  
This statistical analysis was used as the basis to establish a cell culture model to 
identify a direct impact of tRAMs on host-specific innate and adaptive immune 
responses in the background of certain HLA types. Immature monocyte-derived 
dendritic cells (moDCs), the most important antigen presenting cells, were 
transduced using lentiviral vectors to introduce HLA alleles of interest (here: HLA-
A*02:01 and HLA-B*44:03). Subsequently, these moDCs were infected with HIV-1 
ADA_V82A and ADA_L210F, respectively while ADA_V82A included the possible 
immune escape mutant V82A (protease), which is at the same time associated with 
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PI resistance, ADA_L210F carried the already described immune escape mutation 
L210F. In order to study the impact on both, the innate as well as the adaptive 
immune system, infected recombinant moDCs were co-cultured with either 
CD16+CD56+ NK cells or CD8+ T cells. For the screening of characteristic cytokines 
and/or chemokines a human 25-plex luminex assay was used. While the secretion of 
IL-7 is decreased in co-cultures with CD8+ T cells, levels of IL-15 are comparably low 
in co-cultures with CD16+CD56+ NK cells. The secretion of IL-8 is decreased in co-
cultures with both, CD16+CD56+ NK cells and CD8+ T cells, upon encountering the 
putative immune escape mutation in the background of the restricting HLA allele.  
These data identified IL-7, IL-8 and IL-15 as putative biomarkers monitoring immune 
activation regarding immune escape. However, more research has to be done to 
strengthen the role of IL-7, IL-8 and IL-15. 
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7. Zusammenfassung 
Bei therapienaiven HIV-1-Patienten ist das Verständnis der wirtsspezifischen 
angeborenen und adaptiven Immunantwort von großer Bedeutung. Bei diesen 
Patienten ist das Immunsystem der dominierende Faktor, der durch die Selektion von 
Mutationen eine Anpassung des Virus an die HLA-Allele des Wirts beeinflusst. 
Hierbei kann die Immunogenität von Epitopen negativ beeinflusst werden. Bei 
therapieerfahrenen Patienten hingegen steuern antiretrovirale Wirkstoffe die virale 
Evolution. In HIV-1 können sich so resistenzassoziierte Mutationen (RAMs) 
entwickeln und im Zuge einer Transmission weitergegeben werden. Dieses führt 
dazu, dass in ca. 10 % der therapienaiven Patienten persistierende, übertragene 
RAMs gefunden werden. Höchstwahrscheinlich wird die Persistenz von übertragenen 
RAMs durch die HLA-Allele des neuen therapienaiven Wirts beeinflusst. 
Möglicherweise befinden sich diese übertragenen RAMs innerhalb von HLA Klasse I 
restringierten Epitopen und ermöglichen einen Immunescape. Wechselwirkung 
zwischen Immunsystem und antiretroviraler Therapie könnte dadurch, besonders bei 
der Wahl der Erst-Therapie der therapienaiven Patienten mit übertragenen RAMs, 
eine wichtige Rolle spielen. Eine Therapie sollte antiretrovirale Wirkstoffe 
ausschließen, die unter Berücksichtigung der HLA-Allele der verschiedenen 
Patienten, RAMs selektieren, die gleichzeitig einen Immunescape bewirken.  
Mit Hilfe einer statistischen Analyse wurden hier, unter Verwendung des Exakten 
Fisher-Tests und einer Korrektur für multiple Teste, wurden neun signifikante 
Assoziationen zwischen übertragenen Protease-Inhibitor- (PI-), Nukleosid-Reverse-
Transkriptase-Inhibitor-, Nicht-Nukleosid-Reverse-Transkriptase-Inhibitor-RAMs und 
den HLA-Allelen von 139 therapienaiven Patienten identifiziert. Die Ergebnisse 
dieser statistischen Analyse wurde als Grundlage für die Etablierung eines 
Zellkulturmodels genutzt, mit dem der direkte Einfluss von übertragenen RAMs auf 
die wirtsspezifische angeborene und adaptive Immunantwort untersucht werden 
kann. In diesem Zellkulturmodel wurden unreife dendritische Zellen (DC), welche die 
wichtigsten antigen-präsentierenden Zellen darstellen, mit Hilfe von lentiviralen 
Vektoren transduziert, um eine Überexpression von bestimmten HLA-Allelen (hier: 
HLA-A*02:01 und HLA-B*44:03) zu bewirken. Anschließend wurden diese DC mit 
HIV-1 ADA_V82A und ADA_L210F infiziert. Während ADA_V82A die mögliche 
Immunescape Mutante enthielt V82A, welche zusätzlich mit einer PI-Resistenz 
assoziiert ist, trug ADA_L210F die bereits beschriebene Immunescape Mutation: 
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L210F (RT). Um die Auswirkungen des angeborenen und des adaptiven 
Immunsystems auf diese infizierten DC zu untersuchen, wurden diese entweder mit 
CD16+CD56+ NK-Zellen oder mit CD8+ T-Zellen kokultiviert. Das  humane 25-plex 
Luminex Assay unterstützte das Screening nach charakteristischen Zytokinen 
und/oder Chemokinen, die in diesen Kokulturen sekretiert wurden. Während sich die 
verminderte Sekretion von IL-7 in Kokulturen mit CD8+ T-Zellen als charakteristisch 
herauskristallisierte, wurde eine Reduktion von IL-15 in Kokulturen mit CD16+ CD56+ 
NK-Zellen beobachtet. In beiden Kokulturen stellte sich IL-8 als mutmaßlicher Marker 
eines Immunescapes unter Berücksichtigung des entsprechenden HLA-Allels heraus. 
Zusammenfassend deutet vieles darauf hin, IL-7, IL-8 und IL-15 als mögliche 
Biomarker zur Überwachung der Immunaktivierung heranzuziehen. Jedoch sollte das 
Zellkulturmodel genutzt werden, um weitere Immunescape Mutationen zu 
analysieren, und so die Rolle von IL-7, IL-8 und IL-15 als mögliche Biomarker zu 
verifizieren. 
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9. Appendix 
 
(A) 
>IMGTHLA:HLA00005 A*02:01:01:01 1098 bp 
        Length = 1098 
 
  Plus Strand HSPs: 
 
 Score = 5454 (824.4 bits), Expect = 9.8e-243, P = 9.8e-243, Group = 1 
 Identities = 1094/1098 (99%), Positives = 1094/1098 (99%), Strand = Plus / Plus 
 
Query:   150 ATGGCCGTCATGGCGCCCCGAACCCTCGTCCTGCTACTCTCGGGGGCTCTGGCCCTGACC 209 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:     1 ATGGCCGTCATGGCGCCCCGAACCCTCGTCCTGCTACTCTCGGGGGCTCTGGCCCTGACC 60 
 
Query:   210 CAGACCTGGGCGGGCTCTCACTCCATGAGGTATTTCTTCACATCCGTGTCCCGGCCCGGC 269 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:    61 CAGACCTGGGCGGGCTCTCACTCCATGAGGTATTTCTTCACATCCGTGTCCCGGCCCGGC 120 
 
Query:   270 CGCGGGGAGCCCCGCTTCATCGCAGTGGGCTACGTGGACGACACGCAGTTCGTGCGGTTC 329 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   121 CGCGGGGAGCCCCGCTTCATCGCAGTGGGCTACGTGGACGACACGCAGTTCGTGCGGTTC 180 
 
Query:   330 GACAGCGACACCGCGAGCCAGAGGATGGAGCCGCGGGCGCCGTGGATAGAGCAGGAGGGT 389 
             ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   181 GACAGCGACGCCGCGAGCCAGAGGATGGAGCCGCGGGCGCCGTGGATAGAGCAGGAGGGT 240 
 
Query:   390 CCGGAGTATTGGGACGGGGAGACACGGAAAGTGAAGGCCCACTCACAGACTCACCGAGTG 449 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   241 CCGGAGTATTGGGACGGGGAGACACGGAAAGTGAAGGCCCACTCACAGACTCACCGAGTG 300 
 
Query:   450 GACCTGGGGACCCTGCGCGGCTACTACAACCAGAGCGAGGCCGGTTCTCACACCGTCCAG 509 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   301 GACCTGGGGACCCTGCGCGGCTACTACAACCAGAGCGAGGCCGGTTCTCACACCGTCCAG 360 
 
Query:   510 AGGATGTATGGCTGCGACGTGGGGTCGGACTGGCGCTTCCTCCGCGGGTACCACCAGTAC 569 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   361 AGGATGTATGGCTGCGACGTGGGGTCGGACTGGCGCTTCCTCCGCGGGTACCACCAGTAC 420 
 
Query:   570 GCCTACGACGGCAAGGATTACATCGCCCTGAAAGAGGACCTGCGCTCTTGGACCGCGGCG 629 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   421 GCCTACGACGGCAAGGATTACATCGCCCTGAAAGAGGACCTGCGCTCTTGGACCGCGGCG 480 
 
Query:   630 GACATGGCAGCTCAGACCACCAAGCACAAGTGGGAGGCGGCCCATGTGGCGGAGCAGTTG 689 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   481 GACATGGCAGCTCAGACCACCAAGCACAAGTGGGAGGCGGCCCATGTGGCGGAGCAGTTG 540 
 
Query:   690 AGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGGGAAG 749 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   541 AGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACGGGAAG 600 
 
Query:   750 GAGATGCTGCAGCGCACGGACGCCCCCAAAACGCATATGACTCACCACGCTGTCTCTGAC 809 
             |||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   601 GAGACGCTGCAGCGCACGGACGCCCCCAAAACGCATATGACTCACCACGCTGTCTCTGAC 660 
 
Query:   810 CATGAAGCCACCCTGAGGTGCTGGGCCCTGAGCTCCTACCCTGCGGAGATCACACTGACC 869 
             |||||||||||||||||||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct:   661 CATGAAGCCACCCTGAGGTGCTGGGCCCTGAGCTTCTACCCTGCGGAGATCACACTGACC 720 
 
Query:   870 TGGCAGCGGGATGGGGAGGACCAGACCCAGGACACGGAGCTCGTGGAGACCAGGCCTGCA 929 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   721 TGGCAGCGGGATGGGGAGGACCAGACCCAGGACACGGAGCTCGTGGAGACCAGGCCTGCA 780 
 
Query:   930 GGGGATGGAACCTTCCAGAAGTGGGCGGCTGTGGTGGTGCCTTCTGGACAGGAGCAGAGA 989 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   781 GGGGATGGAACCTTCCAGAAGTGGGCGGCTGTGGTGGTGCCTTCTGGACAGGAGCAGAGA 840 
 
Query:   990 TACACCTGCCATGTGCAGCATGAGGGTTTGCCCAAGCCCCTCACCCTGAGATGGGAGCCG 1049 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   841 TACACCTGCCATGTGCAGCATGAGGGTTTGCCCAAGCCCCTCACCCTGAGATGGGAGCCG 900 
 
Query:  1050 TCTTCCCAGCCCACCATCCCCATCGTGGGCATCATTGCTGGCCTGGTTCTCTTTGGAGCT 1109 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   901 TCTTCCCAGCCCACCATCCCCATCGTGGGCATCATTGCTGGCCTGGTTCTCTTTGGAGCT 960 
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Query:  1110 GTGATCACTGGAGCTGTGGTCGCTGCTGTGATGTGGTGGAGGAAGAGCTCAGATAGAAAA 1169 
             |||||||||||||||||||||||||||||||||||| ||||||||||||||||||||||| 
Sbjct:   961 GTGATCACTGGAGCTGTGGTCGCTGCTGTGATGTGGAGGAGGAAGAGCTCAGATAGAAAA 1020 
 
Query:  1170 GGAGGGAGCTACTCTCAGGCTGCAAGCAGTGACAGTGCCCAGGGCTCTGATGTGTCTCTC 1229 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:  1021 GGAGGGAGCTACTCTCAGGCTGCAAGCAGTGACAGTGCCCAGGGCTCTGATGTGTCTCTC 1080 
 
Query:  1230 ACAGCTTGTAAAGTGTGA 1247 
             |||||||||||||||||| 
Sbjct:  1081 ACAGCTTGTAAAGTGTGA 1098 
 
(B) 
>IMGTHLA:HLA00319 B*44:03:01 1089 bp 
        Length = 1089 
 
  Plus Strand HSPs: 
 
 Score = 5430 (820.8 bits), Expect = 1.2e-241, P = 1.2e-241, Group = 1 
 Identities = 1086/1086 (100%), Positives = 1086/1086 (100%), Strand = Plus / Plus 
 
Query:    62 ATGCGGGTCACGGCGCCCCGAACCCTCCTCCTGCTGCTCTGGGGGGCAGTGGCCCTGACC 121 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:     1 ATGCGGGTCACGGCGCCCCGAACCCTCCTCCTGCTGCTCTGGGGGGCAGTGGCCCTGACC 60 
 
Query:   122 GAGACCTGGGCCGGCTCCCACTCCATGAGGTATTTCTACACCGCCATGTCCCGGCCCGGC 181 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:    61 GAGACCTGGGCCGGCTCCCACTCCATGAGGTATTTCTACACCGCCATGTCCCGGCCCGGC 120 
 
Query:   182 CGCGGGGAGCCCCGCTTCATCACCGTGGGCTACGTGGACGACACGCTGTTCGTGAGGTTC 241 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   121 CGCGGGGAGCCCCGCTTCATCACCGTGGGCTACGTGGACGACACGCTGTTCGTGAGGTTC 180 
 
Query:   242 GACAGCGACGCCACGAGTCCGAGGAAGGAGCCGCGGGCGCCATGGATAGAGCAGGAGGGG 301 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   181 GACAGCGACGCCACGAGTCCGAGGAAGGAGCCGCGGGCGCCATGGATAGAGCAGGAGGGG 240 
 
Query:   302 CCGGAGTATTGGGACCGGGAGACACAGATCTCCAAGACCAACACACAGACTTACCGAGAG 361 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   241 CCGGAGTATTGGGACCGGGAGACACAGATCTCCAAGACCAACACACAGACTTACCGAGAG 300 
 
Query:   362 AACCTGCGCACCGCGCTCCGCTACTACAACCAGAGCGAGGCCGGGTCTCACATCATCCAG 421 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   301 AACCTGCGCACCGCGCTCCGCTACTACAACCAGAGCGAGGCCGGGTCTCACATCATCCAG 360 
 
Query:   422 AGGATGTACGGCTGCGACGTGGGGCCGGACGGGCGCCTCCTCCGCGGGTATGACCAGGAC 481 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   361 AGGATGTACGGCTGCGACGTGGGGCCGGACGGGCGCCTCCTCCGCGGGTATGACCAGGAC 420 
 
Query:   482 GCCTACGACGGCAAGGATTACATCGCCCTGAACGAGGACCTGAGCTCCTGGACCGCGGCG 541 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   421 GCCTACGACGGCAAGGATTACATCGCCCTGAACGAGGACCTGAGCTCCTGGACCGCGGCG 480 
 
Query:   542 GACACCGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGGAGCAGCTG 601 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   481 GACACCGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGGAGCAGCTG 540 
 
Query:   602 AGAGCCTACCTGGAGGGCCTGTGCGTGGAGTCGCTCCGCAGATACCTGGAGAACGGGAAG 661 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   541 AGAGCCTACCTGGAGGGCCTGTGCGTGGAGTCGCTCCGCAGATACCTGGAGAACGGGAAG 600 
 
Query:   662 GAGACGCTGCAGCGCGCGGACCCCCCAAAGACACATGTGACCCACCACCCCATCTCTGAC 721 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   601 GAGACGCTGCAGCGCGCGGACCCCCCAAAGACACATGTGACCCACCACCCCATCTCTGAC 660 
 
Query:   722 CATGAGGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACACTGACC 781 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   661 CATGAGGTCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACACTGACC 720 
 
Query:   782 TGGCAGCGGGATGGCGAGGACCAAACTCAGGACACCGAGCTTGTGGAGACCAGACCAGCA 841 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   721 TGGCAGCGGGATGGCGAGGACCAAACTCAGGACACCGAGCTTGTGGAGACCAGACCAGCA 780 
 
Query:   842 GGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCAGAGA 901 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   781 GGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCAGAGA 840 
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Query:   902 TACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGAGCCG 961 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   841 TACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGAGCCG 900 
 
Query:   962 TCTTCCCAGTCCACCGTCCCCATCGTGGGCATTGTTGCTGGCCTGGCTGTCCTAGCAGTT 1021 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   901 TCTTCCCAGTCCACCGTCCCCATCGTGGGCATTGTTGCTGGCCTGGCTGTCCTAGCAGTT 960 
 
Query:  1022 GTGGTCATCGGAGCTGTGGTCGCTGCTGTGATGTGTAGGAGGAAGAGCTCAGGTGGAAAA 1081 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:   961 GTGGTCATCGGAGCTGTGGTCGCTGCTGTGATGTGTAGGAGGAAGAGCTCAGGTGGAAAA 1020 
 
Query:  1082 GGAGGGAGCTACTCTCAGGCTGCGTGCAGCGACAGTGCCCAGGGCTCTGATGTGTCTCTC 1141 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct:  1021 GGAGGGAGCTACTCTCAGGCTGCGTGCAGCGACAGTGCCCAGGGCTCTGATGTGTCTCTC 1080 
 
Query:  1142 ACAGCT 1147 
             |||||| 
Sbjct:  1081 ACAGCT 1086 
 
Figure 13.1 Sequence alignment of (A) HLA-A*02:01 ORF and (B) HLA-B*44:03 ORF with 
reference strains. 
 
Table 13.1 Albumin and WPRE concentrations and calculated normalized WPRE expression 
LV_HLA-A*02 Albumin 
concentration 
DNA WPRE 
concentration 
Normalized WPRE 
expression 
neg. control 19.6 28.9 1.47 
1 14100 12500 0.89 
2 20850 7730 0.37 
3 20800 11200 0.54 
    
LV_HLA-B*44 
1 13000 8790 0.68 
2 27450 10900 0.40 
3 13550 7650 0.56 
    
LV_HLA-GFP 
1 13450 7260 0.54 
2 17800 8700 0.49 
3 23900 8420 0.35 
 
Table 13.2 β-actin and WPRE concentrations and calculated normalized WPRE expression 
LV_HLA-A*02 β-actin concentration RNA WPRE 
concentration 
Normalized WPRE 
expression 
neg. control 19.3 28.9 1.50 
1 68500 22400 0.33 
2 41350 13400 0.32 
3 21300 7600 0.36 
    
LV_HLA-B*44 
1 25900 260000 10.04 
2 49050 414000 8.44 
3 31100 362000 11.64 
    
LV_HLA-GFP 
1 42450 455000 10.72 
2 30300 331000 10.92 
3 52000 543000 10.44 
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(A) 
(B) 
(C) 
(D) 
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(E) 
(F) 
Figure 13.2 Real-time PCR amplification curves of an assay, targeting the integrase region of 
the polymerase gene, used to verify the successful infection of moDCs, deriving from different 
donors with HIV-1 ADA_V82A or ADA_L210F. (A) healthy donor 2 infected with ADA_V82A.     
(B) healthy donor 2 infected with ADA_L210F. (C) healthy donor 3 infected with ADA_V82A.   
(D) healthy donor 3 infected with ADA_L210F. (E) healthy donor 4 infected with ADA_V82A.   
(F) healthy donor 4 infected with ADA_L210F. 
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10. Abbreviations 
°C degree celsius 
% percent 
µ micro 
µL micro liter 
µg microgram 
µm micrometer 
aa amino acids 
AA acrylamid 
Ab antibody 
AEC 3-amino-9-ethylcarbazole 
Ag antigen 
AIDS acquired immunodeficiency syndrome 
AmpR ampicillin resistance gene 
APC antigen presenting cell 
APC allophycocyanin 
APS ammonium persulfate 
Arevir Analysis of HIV resistance mutations 
ATCC American Type Culture Collection 
bp base pair 
BSA bovine serum albumin 
CA capsid protein 
CCLR cell culture lysis reagent 
CCR5 C-C chemokine receptor type 5 
CCl2 / 3 / 4 / 5 / 11 C-C chemokine ligand 2 / 3 / 4 / 5 / 11 
CD4 / 8 / 16 / 56 cluster of differentiation 4 / 8 / 16 / 56 
cDNA complementary DNA 
CMV cytomegalovirus 
CO2 carbon dioxide 
cp crossing point 
CPE cytopathic effect 
cPPT central polypurine tract 
CTL cytotoxic T cell 
CXCL9 / 10 C-X-C chemokine ligand 9 / 10 
DC dendritic cell 
ddNTP dideoxynuceotide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide 
D-PBS Dulbecco’s Phosphate-buffered saline 
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DTT dithiothreitol 
E.coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
eGFP enhanced green fluorescent protein 
ELISPOT enzyme linked immuno spot 
env envelope 
ER endoplasmatic reticulum 
FACS fluorescence-activated cell sorting 
FBS fetal bovine serum 
FDR false discovery rate 
FITC fluorescein isothiocyanate 
g g-force 
g gram 
gag group-specific antigen 
GM-CSF granulocyte macrophage colony-stimulating 
factor 
gp 41 / 120 glycoprotein 41 / 120 
H2O water 
H2O2 hydrogen peroxide 
HAART highly active antiretroviral therapy 
HCl hydrogen chloride 
HF high fidelity 
His histidin 
HIV-1 human immunodeficiency virus type 1 
HLA human leukocyte antigen 
IFN-α / -β / -γ interferon alpha / beta / gamma 
Ig immunoglobulin  
IL-1β / -1RA / -2 / -2R / -12 / -15 / -18 interleukin-1β / -1RA / -2 / -2R / -12 / -15 / -18 
IN integrase 
IP-10 IFN-γ induced protein 10 
KanR kanamycin resistance gene 
kb kilo bases 
kDa kilo dalton 
L liter 
LC langerhans cell 
LPS lipopoysaccharide 
LTR long terminal repeats 
LV lentiviral vector 
MΦ macrophage 
MA matrix protein 
MCP-1 monocyte chemotactic protein-1 
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MFI mean fluorescence intensity 
MgCl2 magnesium chloride 
MgSO4 magnesium sulfate 
MIG monocyte interferon gamma inducing factor 
min Minute 
MIP MΦ inflammatory protein 
mL milliliter 
mm millimeter 
mM millimolar 
moDC monocyte-derived DC 
MOI multiplicity of infection 
mRNA messenger RNA 
NaCl sodium chloride 
NaN3 sodium azide 
NC nucleocapsid protein 
nef negative factor 
NK cell natural killer cell 
nm nanometer  
NNRTI non-nucleoside reverse-transcriptase inhibitor 
NRTI nucleoside / nucleotide reverse transcriptase 
inhibitor 
OD optical density 
OR odds ratio 
ORF open reading frame 
p6 / 24 / 51 / 66 protein 
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cells 
PCR polymerase chain reaction 
PE phycoerythrin 
PEG polythylene glycol 
PerCP peridin chlorophyll A protein 
PFA paraformaldehyde 
pH hydrogen ion concentration 
PI protease inhibitor 
PR protease 
RAM Resistance associated mutation 
RANTES regulated upon activation normal T cell 
expressed and presumably secreted 
RESINA resistance in treatment-naïve HIV-1 infected 
patients 
rev regulator of expression of virion proteins 
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RNA ribonucleic acid 
RRE rev response element 
RT reverse transcriptase 
S2 / 3 safety level 2 / 3 
SAP shrimp alkaline phosphatase 
SDM site-directed mutagenesis 
sec second 
SFFV spleen focus-forming virus 
SIN  
SIV simian immunodeficiency virus 
ss single-stranded 
SV40 simian virus 40 
TAE tris-acetate-EDTA-buffer 
tat trans-activator of transcription 
TCID50 tissue culture infectious dose 50 
TEMED tetramethylethylenediamine 
TLR toll-like receptor 
TNF-α tumor necrosis factor α 
tRAM transmitted RAM 
TSB transformation and storage-buffer 
TU transducing unit 
U unit 
URF unique recombinant forms 
UV ultraviolet 
v volume 
V volt 
vif viral infectivity factor 
vpr viral protein r 
vpu viral protein unique 
VSVg vesicular stomatitis virus G glycoprotein 
w weight 
WPRE woodchuck hepatitis virus posttranscriptional 
regulatory element 
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IUB-Code for amino acids 
A: Adenine   U: Uracil  S: G or C  D: A, G or T 
C: Cytosine K: G or T  W: A or T  H: A, C or T 
G: Guanine M: A or C  Y: C or T  V: A, C or G 
T: Thymine R: A or G  B: C, G or T  N: A, C, G or T 
 
International abbreviations for amino acids 
Alanine ala A   Leucine  leu L 
Arginine arg R   Lysine  lys K 
Aspartic acid asp D   Methionine  met M 
Asparagine asn N   Phenylalanine phe F 
Cysteine cys C   Proline  pro P 
Glutamic acid glu E   Serine  ser S 
Glutamine gln Q   Threonine  thr T 
Glycine gly G   Tryptophan  trp W 
Histidine his H   Tyrosine  tyr Y 
Isoleucine ile I   Valine   val V 
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